Notes_NNS to_TO the_DT Financial_NNP Statements_NNP for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2003_CD 1_CD ._.
Accounting_NNP policies_NNS Accounting_NNP convention_NN The_DT financial_JJ statements_NNS are_VBP prepared_VBN under_IN the_DT historical_JJ cost_NN convention_NN and_CC in_IN accordance_NN with_IN applicable_JJ accounting_NN standards_NNS ._.
Basis_NN of_IN consolidation_NN The_DT consolidated_JJ accounts_NNS include_VBP the_DT results_NNS of_IN the_DT Company_NN and_CC all_DT of_IN its_PRP$ subsidiary_NN undertakings_NNS ._.
No_DT profit_NN and_CC loss_NN account_NN is_VBZ presented_VBN for_IN Celltech_NNP Group_NNP plc_NN ,_, as_IN provided_VBN by_IN section_NN 230_CD of_IN the_DT Companies_NNS Act_NNP 1985_CD ._.
The_DT results_NNS of_IN businesses_NNS acquired_VBN are_VBP included_VBN in_IN the_DT Group_NNP accounts_NNS from_IN their_PRP$ date_NN of_IN acquisition_NN unless_IN they_PRP are_VBP held_VBN for_IN immediate_JJ disposal_NN ._.
Income_NNP recognition_NN Revenue_NN from_IN product_NN sales_NNS is_VBZ recorded_VBN as_IN turnover_NN at_IN the_DT invoiced_JJ amount_NN excluding_VBG sales_NNS and_CC value_NN added_VBD taxes_NNS less_JJR estimated_JJ provisions_NNS for_IN product_NN returns_NNS ,_, wholesale_JJ chargebacks_NNS and_CC rebates_NNS given_VBN to_TO Medicaid_NNP ,_, managed_VBD care_NN and_CC other_JJ customers_NNS ._.
Cash_NN discounts_NNS for_IN prompt_JJ payment_NN are_VBP also_RB deducted_VBN from_IN sales_NNS on_IN an_DT accrual_NN basis_NN ._.
Revenue_NN is_VBZ recognized_VBN when_WRB title_NN passes_VBZ ,_, which_WDT is_VBZ usually_RB either_RB on_IN shipment_NN or_CC on_IN receipt_NN of_IN goods_NNS by_IN the_DT customer_NN ,_, depending_VBG on_IN local_JJ trading_NN terms_NNS ._.
Royalties_NNS are_VBP recorded_VBN as_IN turnover_NN and_CC recognized_VBN on_IN a_DT time_NN accrual_NN basis_NN unless_IN there_EX remains_VBZ uncertainty_NN over_IN their_PRP$ collection_NN ,_, in_IN which_WDT case_NN recognition_NN is_VBZ deferred_VBN until_IN such_JJ uncertainties_NNS are_VBP removed_VBN ,_, which_WDT is_VBZ typically_RB on_IN cash_NN receipt_NN ._.
Revenue_NN under_IN research_NN and_CC development_NN reimbursement_NN contracts_NNS ,_, where_WRB there_EX is_VBZ no_DT obligation_NN to_TO repay_VB such_JJ amounts_NNS ,_, is_VBZ recognized_VBN as_IN the_DT related_JJ costs_NNS are_VBP incurred_VBN and_CC is_VBZ recorded_VBN as_IN a_DT credit_NN to_TO research_NN and_CC development_NN expenditure_NN ._.
Income_NN associated_VBN with_IN performance_NN milestones_NNS is_VBZ recognized_VBN based_VBN upon_IN the_DT occurrence_NN of_IN the_DT event_NN that_WDT triggers_VBZ the_DT milestone_NN payment_NN ,_, as_IN defined_VBN in_IN the_DT respective_JJ agreements_NNS ,_, and_CC is_VBZ recorded_VBN as_IN Other_JJ income_NN ._.
Other_JJ payments_NNS received_VBD ,_, such_JJ as_IN licence_NN fees_NNS ,_, are_VBP assessed_VBN on_IN a_DT case-by-case_JJ basis_NN ,_, taking_VBG into_IN account_NN the_DT nature_NN of_IN the_DT payment_NN and_CC the_DT ongoing_JJ collaboration_NN ,_, if_IN any_DT ,_, with_IN the_DT third_JJ party_NN and_CC any_DT possible_JJ related_VBN continuing_VBG obligations_NNS ._.
Depending_VBG on_IN the_DT nature_NN of_IN the_DT arrangement_NN ,_, amounts_NNS received_VBD may_MD be_VB recognized_VBN immediately_RB as_IN a_DT component_NN of_IN Other_JJ income_NN or_CC deferred_VBN over_IN the_DT development_NN or_CC other_JJ appropriate_JJ period_NN ._.
Goodwill_NNP Goodwill_NNP represents_VBZ the_DT excess_NN of_IN consideration_NN paid_VBN over_IN the_DT fair_JJ value_NN of_IN the_DT net_JJ separable_JJ assets_NNS acquired_VBN at_IN the_DT date_NN of_IN acquisition_NN ._.
Goodwill_NN arising_VBG after_IN 1_CD January_NNP 1998_CD is_VBZ capitalized_VBN and_CC amortised_VBN over_IN its_PRP$ useful_JJ economic_JJ life_NN ,_, normally_RB not_RB exceeding_VBG 20_CD years_NNS ,_, on_IN a_DT straight-line_JJ basis_NN ._.
Prior_RB to_TO 1_CD January_NNP 1998_CD ,_, goodwill_NN was_VBD written_VBN off_RP directly_RB to_TO reserves_NNS and_CC upon_IN disposal_NN would_MD be_VB charged_VBN to_TO the_DT profit_NN and_CC loss_NN account_NN ._.
Intangibles_NNP Intangible_NNP assets_NNS represent_VBP acquired_VBN licences_NNS ,_, patents_NNS ,_, platform_NN technologies_NNS and_CC marketing_NN rights_NNS ,_, where_WRB these_DT relate_VBP to_TO specific_JJ compounds_NNS ,_, products_NNS or_CC know-how_NN that_WDT are_VBP being_VBG developed_VBN or_CC used_VBN for_IN commercial_JJ applications_NNS ._.
Intangible_JJ assets_NNS acquired_VBN separately_RB from_IN a_DT business_NN are_VBP capitalized_VBN at_IN cost_NN ._.
Intangible_JJ assets_NNS acquired_VBN as_IN part_NN of_IN a_DT business_NN are_VBP capitalized_VBN separately_RB where_WRB their_PRP$ value_NN can_MD be_VB measured_VBN reliably_RB :_: otherwise_RB they_PRP are_VBP treated_VBN as_IN part_NN of_IN goodwill_NN acquired_VBN with_IN that_DT business_NN ._.
Separately_NNP capitalized_VBD intangible_JJ assets_NNS are_VBP stated_VBN at_IN cost_NN less_JJR provision_NN for_IN amortisation_NN ._.
Intangible_JJ assets_NNS in_IN relation_NN to_TO licences_NNS ,_, patents_NNS and_CC marketing_NN rights_NNS are_VBP amortised_VBN over_IN their_PRP$ estimated_VBN useful_JJ lives_NNS to_TO match_VB the_DT sales_NNS of_IN the_DT related_JJ products_NNS or_CC ,_, where_WRB this_DT is_VBZ not_RB readily_RB identifiable_JJ ,_, on_IN a_DT straight-line_JJ basis_NN ._.
Estimated_VBN useful_JJ lives_NNS are_VBP reviewed_VBN annually_RB and_CC are_VBP generally_RB presumed_VBN not_RB to_TO exceed_VB 20_CD years_NNS ._.
Platform_NN technologies_NNS supporting_VBG the_DT Groups_NNS discovery_NN research_NN strategy_NN are_VBP considered_VBN to_TO have_VB an_DT indefinite_JJ life_NN and_CC consequently_RB are_VBP subject_JJ to_TO annual_JJ reviews_NNS and_CC amortised_VBN as_RB necessary_JJ if_IN impairment_NN is_VBZ considered_VBN to_TO have_VB taken_VBN place_NN ._.
Research_NNP and_CC Development_NNP Research_NNP and_CC development_NN expenses_NNS include_VBP related_VBN salaries_NNS ,_, contractor_NN fees_NNS ,_, building_VBG costs_NNS ,_, utilities_NNS and_CC allocations_NNS of_IN appropriate_JJ administrative_JJ overheads_NNS ._.
Research_NNP and_CC development_NN costs_NNS also_RB include_VBP activities_NNS such_JJ as_IN product_NN registration_NN and_CC regulatory_JJ costs_NNS ._.
All_DT such_JJ costs_NNS are_VBP charged_VBN to_TO research_NN and_CC development_NN expenditure_NN as_IN incurred_VBN ._.
Depreciation_NN Depreciation_NN is_VBZ provided_VBN on_IN all_DT fixed_VBN assets_NNS at_IN rates_NNS calculated_VBN to_TO write_VB the_DT cost_NN of_IN each_DT asset_NN down_IN to_TO estimated_VBN residual_JJ values_NNS evenly_RB over_IN its_PRP$ expected_VBN useful_JJ life_NN ,_, as_IN follows_VBZ :_: Leasehold_VB properties_NNS and_CC improvements_NNS the_DT shorter_JJR of_IN 20_CD years_NNS or_CC the_DT lease_NN term_NN Freehold_NNP buildings_NNS 50_CD years_NNS Freehold_NNP land_NN no_DT depreciation_NN Plant_NN and_CC machinery_NN 2_CD to_TO 10_CD years_NNS Celltech_NNP Annual_JJ Report_NNP 2003_CD 53_CD Notes_NNS to_TO the_DT Financial_NNP Statements_NNP continued_VBD 1_CD ._.
Accounting_NNP policies_NNS continued_VBD Stocks_NNS Stock_NN of_IN material_NN for_IN use_NN in_IN scheduled_VBN clinical_JJ trials_NNS is_VBZ written_VBN off_RP to_TO investment_NN in_IN research_NN and_CC development_NN upon_IN use_NN or_CC at_IN termination_NN of_IN the_DT trial_NN ._.
Other_JJ stocks_NNS are_VBP stated_VBN at_IN the_DT lower_JJR of_IN cost_NN and_CC net_JJ realisable_JJ value_NN ._.
Leased_JJ assets_NNS Assets_NNS acquired_VBN under_IN finance_NN leasing_VBG arrangements_NNS are_VBP capitalized_VBN at_IN cost_NN upon_IN inception_NN and_CC depreciated_VBN over_IN their_PRP$ expected_VBN useful_JJ lives_NNS ._.
The_DT interest_NN element_NN of_IN the_DT rental_JJ obligations_NNS is_VBZ charged_VBN to_TO the_DT profit_NN and_CC loss_NN account_NN over_IN the_DT period_NN of_IN the_DT lease_NN and_CC represents_VBZ a_DT constant_JJ proportion_NN of_IN the_DT balance_NN of_IN capital_NN repayments_NNS outstanding_JJ ._.
Outstanding_JJ future_JJ lease_NN obligations_NNS are_VBP shown_VBN in_IN Creditors_NNS ._.
Rentals_NNS paid_VBN under_IN operating_VBG leases_NNS are_VBP charged_VBN to_TO the_DT profit_NN and_CC loss_NN account_NN as_IN they_PRP accrue_VBP ._.
Foreign_NNP currencies_NNS The_DT profit_NN and_CC loss_NN accounts_NNS and_CC cash_NN flows_NNS of_IN overseas_JJ subsidiaries_NNS are_VBP translated_VBN into_IN sterling_NN at_IN the_DT average_JJ rates_NNS of_IN exchange_NN ,_, other_JJ than_IN substantial_JJ exceptional_JJ items_NNS which_WDT are_VBP translated_VBN at_IN the_DT rate_NN on_IN the_DT date_NN of_IN the_DT transaction_NN ._.
The_DT adjustment_NN to_TO closing_VBG rates_NNS for_IN the_DT year_NN is_VBZ taken_VBN to_TO reserves_NNS ._.
Balance_NN sheets_NNS are_VBP translated_VBN at_IN closing_NN rates_NNS ._.
Exchange_NNP differences_NNS arising_VBG on_IN the_DT re-translation_NN at_IN closing_NN rates_NNS of_IN the_DT opening_NN balance_NN sheets_NNS of_IN overseas_JJ subsidiaries_NNS are_VBP taken_VBN to_TO reserves_NNS ,_, less_JJR exchange_NN differences_NNS arising_VBG on_IN related_VBN foreign_JJ currency_NN borrowings_NNS ._.
Tax_NNP charges_NNS and_CC credits_NNS arising_VBG on_IN such_JJ items_NNS are_VBP also_RB taken_VBN to_TO reserves_NNS ._.
Other_JJ exchange_NN differences_NNS are_VBP taken_VBN to_TO the_DT profit_NN and_CC loss_NN account_NN ._.
Transactions_NNS in_IN foreign_JJ currencies_NNS are_VBP recorded_VBN at_IN the_DT rate_NN of_IN exchange_NN at_IN the_DT date_NN of_IN the_DT transaction_NN or_CC ,_, if_IN hedged_VBN forward_RB ,_, at_IN the_DT rate_NN of_IN exchange_NN under_IN the_DT related_VBN foreign_JJ currency_NN contract_NN ._.
Monetary_NNP amounts_VBZ denominated_VBN in_IN a_DT foreign_JJ currency_NN are_VBP translated_VBN at_IN closing_NN rates_NNS at_IN the_DT year_NN end_NN ._.
Preference_NN share_NN dividends_NNS Accumulated_VBN unpaid_JJ preference_NN share_NN dividends_NNS have_VBP been_VBN accounted_VBN for_IN as_IN a_DT reserves_NNS accrual_NN ._.
During_IN the_DT year_NN ended_VBD 31_CD December_NNP 2003_CD the_DT preference_NN shares_NNS in_IN existence_NN were_VBD redeemed_VBN see_VBP note_NN 24_CD ._.
Pensions_NNS The_DT Group_NNP operates_VBZ contributory_NN and_CC non-contributory_JJ defined_VBN benefit_NN and_CC defined_VBN contribution_NN pension_NN schemes_NNS covering_VBG the_DT majority_NN of_IN its_PRP$ employees_NNS ._.
The_DT scheme_NN funds_NNS of_IN the_DT defined_VBN benefit_NN plans_NNS are_VBP administered_VBN by_IN trustees_NNS and_CC are_VBP independent_JJ of_IN the_DT Groups_NNS finances_NNS ._.
Contributions_NNS are_VBP paid_VBN to_TO the_DT schemes_NNS in_IN accordance_NN with_IN the_DT recommendations_NNS of_IN independent_JJ actuaries_NNS ._.
The_DT Groups_NNS contributions_NNS are_VBP charged_VBN to_TO the_DT profit_NN and_CC loss_NN account_NN so_RB as_IN to_TO spread_VB the_DT costs_NNS of_IN pensions_NNS over_IN employees_NNS working_VBG lives_NNS with_IN the_DT Group_NNP ._.
As_IN permitted_VBN by_IN SSAP_NNP 24_CD ,_, and_CC as_IN indicated_VBN in_IN note_NN 27_CD ,_, the_DT defined_VBN benefit_NN schemes_NNS of_IN certain_JJ overseas_JJ subsidiaries_NNS are_VBP accounted_VBN for_IN under_IN local_JJ GAAP_NNP due_JJ to_TO the_DT difficulties_NNS and_CC cost_NN of_IN obtaining_VBG the_DT necessary_JJ actuarial_JJ information_NN ._.
Payments_NNS to_TO defined_VBN contributions_NNS schemes_NNS are_VBP expensed_VBN as_IN incurred_VBN ._.
Equity_NNP investments_NNS Current_JJ asset_NN equity_NN investments_NNS are_VBP valued_VBN at_IN the_DT lower_JJR of_IN cost_NN and_CC net_JJ realisable_JJ value_NN ._.
In_IN determining_VBG net_JJ realisable_JJ values_NNS ,_, market_NN values_NNS are_VBP used_VBN in_IN the_DT case_NN of_IN listed_VBN investments_NNS and_CC Directors_NNS estimates_NNS are_VBP used_VBN in_IN the_DT case_NN of_IN unlisted_JJ investments_NNS ._.
Deferred_JJ taxation_NN Deferred_VBN taxation_NN is_VBZ provided_VBN on_IN timing_NN differences_NNS that_WDT have_VBP originated_VBN but_CC not_RB reversed_VBN by_IN the_DT balance_NN sheet_NN date_NN except_IN as_IN otherwise_RB required_VBN by_IN FRS_NNP 19_CD on_IN a_DT non-discounted_JJ basis_NN ._.
Deferred_JJ taxation_NN assets_NNS are_VBP recognized_VBN only_RB to_TO the_DT extent_NN that_IN it_PRP is_VBZ more_RBR likely_JJ than_IN not_RB that_IN there_EX will_MD be_VB suitable_JJ taxable_JJ profits_NNS from_IN which_WDT future_JJ reversals_NNS of_IN the_DT underlying_VBG timing_NN difference_NN can_MD be_VB deducted_VBN ._.
Contingent_JJ liabilities_NNS The_DT Group_NNP is_VBZ involved_VBN in_IN certain_JJ legal_JJ proceedings_NNS arising_VBG in_IN the_DT normal_JJ course_NN of_IN its_PRP$ business_NN ,_, as_IN discussed_VBN in_IN the_DT contingent_JJ liabilities_NNS note_VBP to_TO the_DT financial_JJ statements_NNS see_VBP note_NN 28_CD ._.
Provision_NNP is_VBZ made_VBN in_IN the_DT accounts_NNS for_IN all_DT liabilities_NNS which_WDT might_MD be_VB reasonably_RB expected_VBN to_TO materialise_VB from_IN these_DT claims_NNS ._.
Financial_NNP instruments_NNS The_DT Group_NNP uses_VBZ financial_JJ instruments_NNS ,_, in_IN particular_JJ forward_RB exchange_NN contracts_NNS ,_, to_TO manage_VB the_DT financial_JJ risks_NNS associated_VBN with_IN the_DT Groups_NNS underlying_VBG business_NN activities_NNS and_CC the_DT financing_NN of_IN those_DT foreign_JJ activities_NNS ._.
The_DT Group_NNP does_VBZ not_RB undertake_VB any_DT trading_NN activity_NN in_IN financial_JJ instruments_NNS ._.
A_DT discussion_NN of_IN how_WRB the_DT Group_NNP manages_VBZ its_PRP$ financial_JJ risks_NNS is_VBZ included_VBN in_IN the_DT Financial_NNP Review_NNP and_CC in_IN note_NN 21_CD ._.
The_DT primary_JJ financial_JJ instruments_NNS used_VBN by_IN the_DT Group_NNP are_VBP forward_RB exchange_NN contracts_NNS which_WDT are_VBP used_VBN to_TO hedge_VB foreign_JJ exchange_NN exposures_NNS arising_VBG on_IN forecast_NN receipts_NNS in_IN foreign_JJ currencies_NNS ._.
As_IN the_DT hedges_NNS are_VBP not_RB absolutely_RB matched_VBN to_TO specific_JJ receivables_NN ,_, gains_NNS and_CC losses_NNS are_VBP not_RB recognized_VBN until_IN such_JJ time_NN as_IN they_PRP have_VBP been_VBN realized_VBN ._.
The_DT aggregate_JJ fair_JJ values_NNS at_IN the_DT balance_NN sheet_NN date_NN of_IN the_DT hedging_NN instruments_NNS described_VBN above_IN are_VBP disclosed_VBN in_IN note_NN 21_CD to_TO the_DT accounts_NNS ._.
Analysis_NN of_IN turnover_NN ,_, profit_NN and_CC net_JJ assets_NNS Turnover_NN is_VBZ represented_VBN by_IN product_NN sales_NNS and_CC royalties_NNS receivable_JJ during_IN the_DT year_NN ._.
Income_NNP receivable_NN as_IN milestones_NNS arising_VBG from_IN research_NN and_CC development_NN collaborations_NNS is_VBZ treated_VBN as_IN other_JJ operating_NN income_NN ._.
2003_CD 2002_CD i_FW Turnover_NN by_IN geographical_JJ destination_NN m_NN m_NN USA_NNP 243.7_CD 231.8_CD UK_NNP 51.1_CD 41.9_CD Rest_VBP of_IN Europe_NNP 51.1_CD 48.5_CD Rest_VBP of_IN world_NN 7.4_CD 7.4_CD Total_JJ 353.3_CD 329.6_CD Turnover_NN comprises_VBZ 259.2_CD million_CD 2002_CD :_: 252.9_CD million_CD of_IN product_NN sales_NNS and_CC 94.1_CD million_CD 2002_CD :_: 76.7_CD million_CD of_IN royalty_NN income_NN ._.
Royalty_NN income_NN includes_VBZ 10.5_CD million_CD of_IN forward_RB hedging_VBG exchange_NN gains_NNS ._.
In_IN the_DT year_NN ended_VBD 31_CD December_NNP 2002_CD foreign_JJ exchange_NN gains_NNS of_IN 3.7_CD million_CD are_VBP included_VBN in_IN cost_NN of_IN sales_NNS ._.
The_DT Group_NNP considers_VBZ that_IN the_DT revised_VBN 2003_CD presentation_NN reflects_VBZ more_RBR appropriately_RB the_DT nature_NN of_IN the_DT hedging_VBG transaction_NN ._.
ii_FW Segmental_JJ analysis_NN by_IN country_NN of_IN origin_NN Operating_NN profit_NN loss_NN Loss_NN on_IN ordinary_JJ before_IN goodwill_NN and_CC activities_NNS Turnover_NN exceptional_JJ items_NNS before_IN interest_NN Net_JJ assets_NNS 2003 2002 2003 2002_CD 2003 2002 2003 2002_CD m_NN m_FW m_FW m_FW m_FW m_FW m_FW m_FW USA_NNP 168.4_CD 162.5_CD 52.3_CD 41.5_CD 17.4_CD 18.1_CD 234.1_CD 313.2_CD UK_NNP 132.0_CD 116.2_CD 11.7_CD 3.2_CD 57.1_CD 24.9_CD 216.8_CD 186.0_CD Rest_VBP of_IN Europe_NNP 52.9_CD 50.9_CD 8.9_CD 10.7_CD 10.7_CD 1.7_CD 55.0_CD 65.2_CD Total_JJ 353.3_CD 329.6_CD 49.5_CD 49.0_CD 85.2_CD 44.7_CD 505.9_CD 564.4_CD Substantially_NNP all_DT of_IN the_DT turnover_NN and_CC operating_VBG profits_NNS are_VBP generated_VBN from_IN the_DT Groups_NNS principal_JJ activity_NN ,_, being_VBG the_DT research_NN and_CC development_NN of_IN novel_NN therapeutic_JJ products_NNS for_IN human_JJ use_NN and_CC the_DT development_NN ,_, manufacture_NN and_CC sale_NN of_IN prescription_NN pharmaceutical_JJ products_NNS ._.
Other_JJ income_NN 2003_CD 2002_CD m_NN m_NN Pfizer_NNP CDP870_NNP milestone_NN 6.4_CD Other_JJ milestone_NN income_NN 1.5_CD 1.7_CD Disposal_NNP of_IN product_NN licences_NNS 0.5_CD Other_JJ collaboration_NN income_NN 0.5_CD Total_JJ 2.5_CD 8.1_CD During_IN the_DT year_NN Pfizer_NNP gave_VBD notice_NN of_IN their_PRP$ intention_NN to_TO terminate_VB their_PRP$ participation_NN in_IN the_DT development_NN of_IN CDP870_CD from_IN February_NNP 2004_CD ,_, consequently_RB no_DT further_JJ income_NN will_MD be_VB received_VBN from_IN Pfizer_NNP with_IN regard_NN to_TO this_DT collaboration_NN ._.
An_DT amount_NN of_IN 4.8_CD million_CD 2002_CD :_: 5.4_CD million_CD is_VBZ held_VBN on_IN the_DT balance_NN sheet_NN within_IN accruals_NNS and_CC deferred_JJ income_NN ,_, in_IN respect_NN of_IN Pfizers_NNP upfront_NN contribution_NN to_TO the_DT development_NN of_IN CDP870_NNP in_IN the_DT Crohns_NNP disease_NN indication_NN ._.
This_DT amount_NN has_VBZ been_VBN deferred_VBN and_CC is_VBZ being_VBG taken_VBN to_TO income_NN over_IN the_DT remaining_VBG development_NN period_NN ,_, in_IN order_NN to_TO match_VB the_DT revenue_NN with_IN the_DT associated_VBN cost_NN ._.
Research_NNP and_CC development_NN expenditure_NN in_IN 2003_CD is_VBZ shown_VBN net_NN of_IN the_DT 0.6_CD million_CD 2002_CD :_: 3.7_CD million_CD of_IN the_DT upfront_JJ contribution_NN utilised_VBN during_IN the_DT year_NN ._.
Celltech_NNP Annual_JJ Report_NNP 2003_CD 55_CD Notes_NNS to_TO the_DT Financial_NNP Statements_NNP continued_VBD 4_CD ._.
Operating_VBG loss_NN The_DT operating_NN loss_NN is_VBZ stated_VBN after_IN charging_VBG :_: 2003_CD 2002_CD m_NN m_NN Depreciation_NN owned_VBN assets_NNS 13.5_CD 12.8_CD Depreciation_NN assets_NNS held_VBN under_IN finance_NN leases_VBZ 0.4_CD 0.5_CD Amortisation_NNP intangibles_VBZ 3.2_CD 1.0_CD Operating_NN lease_NN rentals_NNS plant_NN and_CC machinery_NN 1.1_CD 1.4_CD Operating_NN lease_NN rentals_NNS other_JJ 6.3_CD 6.4_CD Administrative_JJ expenses_NNS corporate_JJ and_CC general_JJ administrative_JJ 31.3_CD 26.8_CD Depreciation_NN exceptional_JJ items_NNS 18.9_CD Depreciation_NN goodwill_NN 94.2_CD 93.7_CD In_IN 2003_CD the_DT operating_NN loss_NN is_VBZ also_RB stated_VBN after_IN the_DT following_VBG material_NN items_NNS discussed_VBD elsewhere_RB in_IN this_DT report_NN :_: 10.5_CD million_CD 2002_CD :_: 3.7_CD million_CD of_IN exchange_NN gains_NNS on_IN hedging_VBG instruments_NNS note_VBP 2_CD and_CC 3.0_CD million_CD 2002_CD :_: 2.9_CD million_CD establishment_NN of_IN new_JJ provisions_NNS for_IN self_NN insurance_NN note_NN 20_CD ._.
In_IN addition_NN in_IN 2002_CD ,_, there_EX was_VBD a_DT provision_NN release_NN of_IN 3.1_CD million_CD note_NN 20_CD and_CC a_DT 0.9_CD million_CD loss_NN on_IN the_DT disposal_NN of_IN equity_NN investments_NNS note_VBP 16_CD ._.
Fees_NNS paid_VBD to_TO auditors_NNS The_DT following_JJ summarises_NNS the_DT audit_NN and_CC non-audit_JJ fees_NNS paid_VBN to_TO the_DT auditor_NN ,_, KPMG_NNP Audit_NNP Plc_NNP :_: 2003_CD 2002_CD m_NN m_NN Audit_NNP services_NNS 0.4_CD 0.3_CD Further_JJ assurance_NN services_NNS 0.3_CD 0.1_CD Tax_NNP services_NNS compliance_NN 0.2_CD 0.2_CD Tax_NNP services_NNS advisory_JJ 0.1_CD 0.2_CD Total_JJ 1.0_CD 0.8_CD The_DT Company_NN audit_NN fee_NN amounted_VBD to_TO 25,000_CD 2002_CD :_: 25,000_CD ._.
There_EX are_VBP no_DT fees_NNS charged_VBN to_TO the_DT Company_NN for_IN other_JJ services_NNS ._.
Exceptional_JJ items_NNS 2003_CD 2002_CD m_NN m_NN European_JJ sales_NNS force_NN restructuring_NN 9.0_CD Write-off_NN CDP571_CD stocks_NNS 7.5_CD Development_NNP restructuring_NN 1.5_CD Thiemann_NNP asset_NN write-down_NN 0.9_CD Operating_NN exceptional_JJ charge_NN 18.9_CD Loss_NN on_IN the_DT termination_NN of_IN operations_NNS 14.6_CD Provision_NNP against_IN fixed_VBN asset_NN investment_NN 7.0_CD Exceptional_JJ items_NNS before_IN taxation_NN 40.5_CD Exceptional_JJ tax_NN items_NNS note_VBP 8_CD 31.7_CD Exceptional_JJ items_NNS 8.8_CD Of_IN the_DT total_JJ exceptional_JJ charge_NN of_IN 40.5_CD million_CD before_IN taxation_NN ,_, 20.0_CD million_CD will_MD result_VB in_IN a_DT cash_NN outflow_NN for_IN the_DT Group_NNP and_CC 20.5_CD million_CD represents_VBZ asset_NN write-downs_NNS ._.
The_DT non-cash_JJ items_NNS are_VBP the_DT write-off_NN of_IN the_DT investment_NN in_IN Neogenesis_NNP and_CC CDP571_NNP stocks_NNS together_RB totalling_VBG 14.5_CD million_CD ,_, tangible_JJ fixed_JJ asset_NN impairments_NNS of_IN 4.5_CD million_CD see_VBP note_NN 12_CD and_CC 1.5_CD million_CD of_IN inventory_NN write-downs_NNS at_IN the_DT Santa_NNP Ana_NNP manufacturing_VBG facility_NN ._.
The_DT total_JJ cash_NN expenditure_NN on_IN exceptional_JJ items_NNS in_IN the_DT year_NN ended_VBD 31_CD December_NNP 2003_CD was_VBD 8.9_CD million_CD 8.7_CD million_CD of_IN items_NNS booked_VBN in_IN the_DT current_JJ year_NN and_CC 0.2_CD million_CD of_IN prior_JJ year_NN items_NNS ,_, leaving_VBG a_DT balance_NN of_IN 11.3_CD million_CD to_TO be_VB spent_VBN primarily_RB during_IN 2004_CD ._.
The_DT total_JJ cash_NN cost_NN of_IN 20.0_CD million_CD includes_VBZ 14.5_CD million_CD of_IN redundancy_NN and_CC related_JJ costs_NNS ._.
Operating_VBG exceptional_JJ items_NNS European_JJ sales_NNS force_NN restructuring_NN During_IN the_DT year_NN the_DT UK_NNP ,_, French_NNP ,_, German_NNP and_CC Spanish_JJ sales_NNS forces_NNS have_VBP been_VBN restructured_VBN from_IN primary_JJ care_NN to_TO specialist_NN focus_NN ._.
The_DT majority_NN of_IN the_DT costs_NNS in_IN all_DT locations_NNS relate_VBP to_TO provisions_NNS for_IN redundancy_NN and_CC related_VBN expenditure_NN ._.
As_IN at_IN 31_CD December_NNP ,_, 2003_CD ,_, 4.8_CD million_CD of_IN this_DT provision_NN remained_VBD to_TO be_VB utilised_VBN ._.
Exceptional_JJ items_NNS continued_VBD Write-off_NN of_IN CDP571_CD stocks_NNS Following_VBG a_DT review_NN of_IN CDP571_CD undertaken_VBN during_IN 2003_CD ,_, it_PRP was_VBD determined_VBN that_IN the_DT commercial_JJ opportunities_NNS for_IN this_DT product_NN ,_, including_VBG its_PRP$ use_NN on_IN a_DT named_VBN patient_NN basis_NN ,_, would_MD not_RB be_VB actively_RB pursued_VBN ._.
Consequently_RB ,_, the_DT stock_NN of_IN CDP571_CD held_VBD as_RB at_IN 31_CD December_NNP 2002_CD 7.5_CD million_CD has_VBZ been_VBN written_VBN down_RP to_TO nil_NN ._.
Development_NNP restructuring_NN These_DT costs_NNS relate_VBP primarily_RB to_TO the_DT Groups_NNS announced_VBD reorganisation_NN of_IN the_DT development_NN functions_NNS of_IN the_DT Group_NNP based_VBN in_IN Slough_NNP and_CC Cambridge_NNP ._.
The_DT charge_NN relates_VBZ to_TO provision_NN for_IN redundancy_NN costs_NNS and_CC external_JJ consulting_NN costs_NNS ._.
As_IN at_IN 31_CD December_NNP 2003_CD ,_, 0.9_CD million_CD of_IN the_DT total_JJ provision_NN remained_VBD to_TO be_VB utilised_VBN ._.
Thiemann_NNP asset_NN write-down_NN With_IN the_DT acquisition_NN of_IN Thiemann_NNP in_IN 2001_CD ,_, the_DT Group_NNP inherited_VBD a_DT freehold_NN building_NN in_IN Waltrop_NNP in_IN north-east_JJ Germany_NNP ._.
During_IN 2002_CD ,_, Celltechs_NNP German_NNP operations_NNS relocated_VBD to_TO new_JJ leased_VBN offices_NNS in_IN the_DT Essen_NNP area_NN of_IN Germany_NNP ._.
The_DT charge_NN in_IN 2003_CD reflects_VBZ a_DT write-down_NN to_TO net_JJ realisable_JJ value_NN of_IN the_DT Waltrop_NNP site_NN ._.
Loss_NN on_IN termination_NN of_IN operations_NNS The_DT table_NN below_IN sets_NNS out_IN the_DT loss_NN on_IN termination_NN of_IN operations_NNS :_: m_VB Closure_NN of_IN Seattle_NNP research_NN operations_NNS 5.6_CD Closure_NN of_IN Santa_NNP Ana_NNP manufacturing_VBG facility_NN 4.5_CD OGS_NNP closure_NN costs_VBZ 4.5_CD Total_JJ 14.6_CD Closure_NN of_IN Seattle_NNP research_NN operation_NN Following_VBG a_DT review_NN of_IN Celltechs_NNP long-term_JJ research_NN and_CC development_NN needs_NNS ,_, the_DT decision_NN was_VBD made_VBN to_TO close_VB its_PRP$ Seattle_NNP research_NN facility_NN ._.
This_DT closure_NN has_VBZ resulted_VBN in_IN an_DT exceptional_JJ charge_NN of_IN 5.6_CD million_CD ,_, reflecting_VBG provision_NN for_IN redundancy_NN costs_NNS ,_, short-term_JJ lease_NN commitments_NNS and_CC writing_VBG down_RP the_DT remaining_VBG book_NN value_NN of_IN the_DT facility_NN to_TO nil_NN ._.
As_IN at_IN 31_CD December_NNP 2003_CD ,_, 3.4_CD million_CD of_IN the_DT provision_NN remained_VBD to_TO be_VB utilised_VBN ._.
Closure_NN of_IN Santa_NNP Ana_NNP manufacturing_VBG facility_NN On_IN 3_CD June_NNP 2003_CD Celltech_NNP announced_VBD the_DT closure_NN of_IN its_PRP$ manufacturing_NN facility_NN in_IN Santa_NNP Ana_NNP ,_, California_NNP ._.
The_DT site_NN produced_VBD various_JJ methylphenidate_NN products_NNS ._.
Production_NN associated_VBN with_IN the_DT tableting_NN and_CC packaging_NN of_IN these_DT products_NNS has_VBZ been_VBN transferred_VBN to_TO the_DT Groups_NNS facility_NN in_IN Rochester_NNP ,_, New_NNP York_NNP ._.
The_DT provision_NN for_IN closure_NN costs_NNS relates_VBZ primarily_RB to_TO redundancies_NNS ,_, lease_NN commitments_NNS and_CC asset_NN write-downs_NNS ._.
As_IN at_IN 31_CD December_NNP 2003_CD ,_, 0.5_CD million_CD of_IN the_DT provision_NN remained_VBD to_TO be_VB utilised_VBN ._.
OGS_NNP closure_NN costs_NNS Following_VBG Celltechs_NNP acquisition_NN of_IN OGS_NNP ,_, a_DT substantial_JJ restructuring_NN of_IN the_DT operations_NNS was_VBD undertaken_VBN ._.
The_DT charge_NN relates_VBZ primarily_RB to_TO provision_NN for_IN redundancy_NN costs_NNS for_IN staff_NN and_CC development_NN spend_VBP on_IN projects_NNS to_TO be_VB discontinued_VBN ._.
As_IN at_IN 31_CD December_NNP 2003_CD 1.7_CD million_CD of_IN the_DT provision_NN remained_VBD to_TO be_VB utilised_VBN ._.
Provision_NN against_IN fixed_VBN asset_NN investment_NN Neogenesis_NNP investment_NN write-off_NN In_IN view_NN of_IN the_DT current_JJ environment_NN for_IN biotechnology_NN IPOs_NNS ,_, the_DT Directors_NNS have_VBP determined_VBN that_IN the_DT estimated_VBN net_JJ realisable_JJ value_NN of_IN Celltechs_NNP investment_NN in_IN Neogenesis_NNP in_IN the_DT event_NN of_IN a_DT trade_NN sale_NN is_VBZ nil_NN ,_, leading_VBG to_TO a_DT write-down_NN of_IN 7.0_CD million_CD see_VBP note_NN 13_CD ._.
Net_JJ interest_NN receivable_NN 2003_CD 2002_CD m_NN m_NN Bank_NNP interest_NN receivable_NN 3.5_CD 1.4_CD Interest_NN on_IN PowderJect_NNP convertible_JJ loan_NN note_NN receivable_JJ 1.8_CD 2.2_CD Tillotts_NNPS loan_NN note_NN 0.1_CD 0.1_CD 5.4_CD 3.7_CD Interest_NN payable_JJ on_IN $_$ 50m_CD senior_JJ debt_NN 1.9_CD 2.2_CD Interest_NN payable_JJ on_IN revolving_VBG credit_NN facility_NN 0.6_CD Interest_NN paid_VBN on_IN finance_NN leases_VBZ 0.1_CD 0.1_CD Other_JJ 0.1_CD 2.7_CD 2.3_CD Net_JJ interest_NN receivable_NN 2.7_CD 1.4_CD Celltech_NNP Annual_JJ Report_NNP 2003_CD 57_CD Notes_NNS to_TO the_DT Financial_NNP Statements_NNP continued_VBD 7_CD ._.
Staff_NN costs_NNS i_FW Staff_NN costs_NNS ,_, including_VBG the_DT emoluments_NNS of_IN the_DT Executive_NNP Directors_NNS ,_, amounted_VBD to_TO :_: 2003_CD 2002_CD m_NN m_NN Salaries_NNS 81.9_CD 79.4_CD Social_NNP security_NN costs_NNS 8.0_CD 7.4_CD Other_JJ costs_NNS including_VBG pensions_NNS 9.4_CD 10.8_CD Total_JJ 99.3_CD 97.6_CD The_DT above_JJ costs_NNS exclude_VBP redundancy_NN and_CC related_JJ charges_NNS made_VBN during_IN the_DT year_NN of_IN 14.5_CD million_CD see_VBP note_NN 5_CD ._.
ii_FW The_DT average_JJ number_NN of_IN staff_NN employed_VBN by_IN the_DT Group_NNP ,_, including_VBG Executive_NNP Directors_NNS ,_, during_IN the_DT year_NN was_VBD :_: 2003_CD 2002_CD Number_NNP Number_NNP Production_NNP 556_CD 569_CD Sales_NNS and_CC distribution_NN 560_CD 679_CD General_NNP and_CC administration_NN 162_CD 176_CD Research_NNP and_CC technical_JJ 661_CD 613_CD Total_JJ 1,939_CD 2,037_CD iii_FW Details_NNS of_IN the_DT remuneration_NN of_IN each_DT Director_NNP ,_, compensation_NN for_IN loss_NN of_IN office_NN ,_, pension_NN entitlements_NNS and_CC share_NN options_NNS are_VBP included_VBN in_IN the_DT Remuneration_NNP Report_NNP ._.
Taxation_NNP 2003_CD 2002_CD m_NN m_NN UK_NNP corporation_NN tax_NN at_IN 30_CD %_NN 2002_CD :_: 30_CD %_NN 1.3_CD 0.7_CD Utilisation_NNP of_IN tax_NN losses_NNS 1.3_CD 0.7_CD UK_NNP corporation_NN tax_NN Overseas_JJ federal_JJ and_CC state_NN tax_NN 7.6_CD 4.7_CD Overseas_JJ deferred_JJ tax_NN 31.5_CD 2.9_CD Overseas_JJ taxation_NN 23.9_CD 7.6_CD Deferred_JJ tax_NN credit_NN on_IN goodwill_NN 4.7_CD 5.1_CD Taxation_NNP charge_NN 28.6_CD 2.5_CD The_DT table_NN below_IN reconciles_NNS the_DT actual_JJ current_JJ tax_NN charge_NN to_TO the_DT expected_VBN tax_NN rate_NN ,_, computed_VBN by_IN applying_VBG the_DT UK_NNP tax_NN rate_NN of_IN 30_CD %_NN 2002_CD :_: 30_CD %_NN to_TO the_DT loss_NN on_IN ordinary_JJ activities_NNS before_IN taxation_NN :_: 2003_CD 2002_CD m_NN m_NN Expected_VBN tax_NN credit_NN at_IN UK_NNP corporation_NN tax_NN rate_NN 24.8_CD 13.0_CD Permanent_JJ difference_NN on_IN goodwill_NN 24.5_CD 23.3_CD Restructuring_NN costs_NNS see_VBP below_IN 9.5_CD 4.7_CD Difference_NN in_IN local_JJ tax_NN rates_NNS 0.1_CD 0.3_CD Utilisation_NNP of_IN losses_NNS 1.3_CD Other_JJ 1.5_CD 0.1_CD Current_JJ taxation_NN charge_NN 7.6_CD 4.7_CD The_DT deferred_VBN taxation_NN provision_NN at_IN the_DT end_NN of_IN the_DT year_NN is_VBZ set_VBN out_RP below_IN :_: 2003_CD 2002_CD m_NN m_NN Accelerated_VBD capital_NN allowances_NNS 2.2_CD 3.6_CD Goodwill_NNP deferred_VBN tax_NN asset_NN 4.7_CD Other_JJ non-current_JJ tax_NN liabilities_NNS 22.8_CD 53.7_CD Deferred_JJ taxation_NN provision_NN 20.3_CD 57.3_CD 58_CD Celltech_NNP Annual_JJ Report_NNP 2003_CD 8_CD ._.
Taxation_NNP continued_VBD The_DT movement_NN in_IN the_DT provision_NN in_IN the_DT year_NN is_VBZ set_VBN out_RP in_IN note_NN 20_CD ._.
There_EX are_VBP taxation_NN losses_NNS of_IN approximately_RB 289_CD million_CD 2002_CD :_: 291_CD million_CD which_WDT have_VBP not_RB been_VBN recognized_VBN ._.
Exceptional_JJ and_CC goodwill_NN items_NNS 2003_CD m_NN Tax_NNP credit_NN on_IN exceptional_JJ items_NNS 3.2_CD Release_NNP of_IN other_JJ non-current_JJ tax_NN liabilities_NNS 28.5_CD Total_JJ exceptional_JJ tax_NN items_NNS 31.7_CD FRS_NNP 19_CD deferred_JJ tax_NN credit_NN on_IN goodwill_NN 4.7_CD Exceptional_JJ tax_NN and_CC goodwill_NN items_NNS 36.4_CD Tax_NNP credits_NNS on_IN exceptional_JJ items_NNS arising_VBG during_IN the_DT year_NN are_VBP primarily_RB in_IN respect_NN of_IN restructuring_NN charges_NNS outside_IN the_DT UK_NNP ._.
Where_WRB restructuring_NN charges_NNS have_VBP led_VBN to_TO an_DT increase_NN in_IN taxation_NN losses_NNS ,_, the_DT benefit_NN of_IN such_JJ losses_NNS have_VBP not_RB been_VBN recognized_VBN ._.
In_IN addition_NN ,_, as_IN a_DT result_NN of_IN the_DT Group_NNP resolving_VBG a_DT number_NN of_IN outstanding_JJ tax_NN issues_NNS with_IN various_JJ tax_NN authorities_NNS during_IN the_DT course_NN of_IN the_DT year_NN ,_, an_DT amount_NN of_IN 28.5_CD million_CD held_VBN primarily_RB by_IN Medeva_NNP at_IN January_NNP 2000_CD has_VBZ been_VBN released_VBN as_IN an_DT exceptional_JJ credit_NN ._.
FRS_NNP 19_CD Deferred_NNP Tax_NNP requires_VBZ that_IN the_DT Group_NNP recognizes_VBZ deferred_JJ tax_NN assets_NNS in_IN respect_NN of_IN the_DT timing_NN difference_NN associated_VBN with_IN goodwill_NN ._.
This_DT has_VBZ resulted_VBN in_IN the_DT Group_NNP recognizing_VBG a_DT deferred_JJ tax_NN asset_NN of_IN 4.7_CD million_CD in_IN the_DT year_NN ._.
It_PRP is_VBZ anticipated_VBN that_IN additional_JJ deferred_JJ tax_NN assets_NNS will_MD be_VB recognized_VBN in_IN subsequent_JJ years_NNS before_IN reversing_VBG in_IN accordance_NN with_IN the_DT nature_NN of_IN the_DT timing_NN difference_NN ._.
Earnings_NNS per_IN share_NN The_DT basic_JJ loss_NN per_IN share_NN is_VBZ based_VBN upon_IN a_DT loss_NN of_IN 54.0_CD million_CD 2002_CD :_: loss_NN of_IN 46.0_CD million_CD after_IN deduction_NN of_IN preference_NN share_NN dividends_NNS of_IN 0.1_CD million_CD 2002_CD :_: 0.2_CD million_CD and_CC a_DT weighted_JJ average_JJ number_NN of_IN shares_NNS in_IN issue_NN of_IN 276.4_CD million_CD 2002_CD :_: 275.4_CD million_CD ._.
The_DT earnings_NNS per_IN share_NN before_IN goodwill_NN and_CC exceptional_JJ items_NNS is_VBZ provided_VBN based_VBN on_IN a_DT profit_NN of_IN 44.3_CD million_CD 2002_CD :_: profit_NN of_IN 42.6_CD million_CD ._.
This_DT is_VBZ reconciled_VBN to_TO the_DT loss_NN of_IN 54.0_CD million_CD 2002_CD :_: loss_NN of_IN 46.0_CD million_CD as_IN set_VBN out_RP below_IN :_: 2003_CD 2002_CD m_NN m_NN Attributable_JJ loss_NN 54.0_CD 46.0_CD Goodwill_NNP amortisation_NN note_NN 11_CD 94.2_CD 93.7_CD Exceptional_JJ items_NNS note_VBP 5_CD 40.5_CD Tax_NNP on_IN goodwill_NN and_CC exceptional_JJ tax_NN items_NNS note_VBP 8_CD 36.4_CD 5.1_CD Adjusted_JJ profit_NN 44.3_CD 42.6_CD The_DT Directors_NNS believe_VBP that_IN earnings_NNS per_IN share_NN based_VBN on_IN the_DT adjusted_JJ profit_NN provides_VBZ useful_JJ additional_JJ information_NN for_IN shareholders_NNS ._.
The_DT diluted_JJ earnings_NNS loss_NN per_IN share_NN takes_VBZ into_IN account_NN the_DT dilutive_JJ effect_NN of_IN share_NN options_NNS and_CC convertible_JJ preference_NN shares_NNS ._.
A_DT reconciliation_NN between_IN the_DT number_NN of_IN shares_NNS used_VBN in_IN the_DT calculation_NN of_IN the_DT basic_JJ and_CC diluted_JJ earnings_NNS loss_NN per_IN share_NN is_VBZ shown_VBN in_IN the_DT table_NN below_IN :_: 2003_CD 2002_CD Number_NNP Number_NNP m_FW m_FW Basic_JJ weighted_JJ average_JJ number_NN of_IN shares_NNS 276.4_CD 275.4_CD Share_NN options_NNS 1.1_CD 0.6_CD Convertible_JJ preference_NN shares_NNS 0.5_CD 1.9_CD Diluted_NNP number_NN of_IN shares_NNS 278.0_CD 277.9_CD Due_JJ to_TO the_DT loss-making_JJ position_NN of_IN the_DT Group_NNP ,_, the_DT exercise_NN of_IN share_NN options_NNS and_CC conversion_NN of_IN preference_NN shares_NNS do_VBP not_RB increase_VB the_DT basic_JJ loss_NN per_IN share_NN and_CC therefore_RB ,_, according_VBG to_TO FRS_NNP 14_CD the_DT basic_JJ and_CC diluted_JJ loss_NN per_IN share_NN remain_VBP the_DT same_JJ ._.
The_DT 2003_CD and_CC 2002_CD earnings_NNS per_IN share_NN before_IN goodwill_NN and_CC exceptional_JJ items_NNS and_CC the_DT preference_NN share_NN dividend_NN have_VBP been_VBN adjusted_VBN for_IN the_DT dilutive_JJ effect_NN ._.
Profit_NN attributable_JJ to_TO members_NNS of_IN the_DT holding_VBG company_NN In_IN accordance_NN with_IN the_DT exemption_NN allowed_VBN by_IN Section_NN 230_CD of_IN the_DT Companies_NNS Act_NNP 1985_CD the_DT Company_NN has_VBZ not_RB presented_VBN its_PRP$ own_JJ profit_NN and_CC loss_NN account_NN ._.
The_DT profit_NN in_IN the_DT financial_JJ statements_NNS of_IN the_DT Company_NN was_VBD 4.9_CD million_CD 2002_CD :_: profit_NN 6.8_CD million_CD ._.
Celltech_NNP Annual_JJ Report_NNP 2003_CD 59_CD Notes_NNS to_TO the_DT Financial_NNP Statements_NNP continued_VBD 11_CD ._.
Intangible_JJ fixed_JJ assets_NNS Goodwill_NNP Intangible_NNP assets_NNS Group_NNP m_FW m_FW m_FW Cost_NN At_IN 1_CD January_NNP 2003_CD 1,011.7_CD 48.1_CD 1,059.8_CD Additions_NNS 1.8_CD 1.8_CD Acquisition_NNP of_IN OGS_NNP 8.1_CD 8.1_CD Exchange_NNP 1.0_CD 1.0_CD At_IN 31_CD December_NNP 2003_CD 1,019.8_CD 48.9_CD 1,068.7_CD Provisions_NNS for_IN amortisation_NN At_IN 1_CD January_NNP 2003_CD 618.9_CD 1.0_CD 619.9_CD Amortisation_NNP charged_VBN in_IN the_DT year_NN 94.2_CD 3.2_CD 97.4_CD At_IN 31_CD December_NNP 2003_CD 713.1_CD 4.2_CD 717.3_CD Net_JJ book_NN value_NN At_IN 31_CD December_NNP 2003_CD 306.7_CD 44.7_CD 351.4_CD At_IN 31_CD December_NNP 2002_CD 392.8_CD 47.1_CD 439.9_CD The_DT goodwill_NN amortisation_NN charge_NN reflects_VBZ a_DT full_JJ year_NN of_IN ownership_NN of_IN Medeva_NNP 88.3_CD million_CD ,_, Cistron_NNP 0.7_CD million_CD and_CC Thiemann_NNP 4.7_CD million_CD and_CC an_DT eight-month_JJ charge_NN in_IN respect_NN of_IN OGS_NNP of_IN 0.5_CD million_CD see_VBP note_NN 22_CD ._.
Medeva_NNP and_CC Thiemann_NNP goodwill_NN is_VBZ being_VBG amortised_VBN over_IN seven_CD years_NNS ._.
Cistron_NNP and_CC OGS_NNP goodwill_NN is_VBZ being_VBG amortised_VBN over_IN 10_CD years_NNS ._.
Included_VBN within_IN intangible_JJ assets_NNS is_VBZ a_DT payment_NN of_IN 11.8_CD million_CD to_TO Abgenix_NNP for_IN extensive_JJ access_NN to_TO its_PRP$ SLAM_NNP Selective_NNP Lymphocyte_NNP Antibody_NNP Method_NNP technology_NN ._.
Amortisation_NNP has_VBZ not_RB been_VBN charged_VBN on_IN this_DT in_IN the_DT year_NN as_IN the_DT Directors_NNS consider_VBP that_IN it_PRP has_VBZ an_DT indefinite_JJ life_NN ._.
As_IN required_VBN by_IN FRS_NNP 10_CD ,_, Goodwill_NNP and_CC Intangible_NNP Assets_NNPS ,_, the_DT Directors_NNS have_VBP undertaken_VBN an_DT impairment_NN review_NN to_TO support_VB the_DT carrying_VBG value_NN ._.
The_DT SLAM_NNP technology_NN has_VBZ been_VBN combined_VBN with_IN the_DT Groups_NNS existing_VBG antibody_NN technologies_NNS in_IN order_NN to_TO expand_VB the_DT breadth_NN of_IN the_DT antibody_NN pipeline_NN and_CC extend_VB the_DT repertoire_NN of_IN drug_NN targets_NNS ._.
The_DT technology_NN is_VBZ seen_VBN as_IN core_NN to_TO Celltechs_NNP research_NN activities_NNS and_CC will_MD continue_VB to_TO benefit_VB the_DT Group_NNP for_IN the_DT foreseeable_JJ future_NN ,_, accordingly_RB Celltech_NNP has_VBZ rebutted_VBN the_DT presumption_NN that_WDT useful_JJ economic_JJ life_NN should_MD be_VB no_RB longer_RB than_IN 20_CD years_NNS as_IN permitted_VBN by_IN FRS_NNP 10_CD ,_, Goodwill_NNP and_CC Intangible_NNP Assets_NNPS ._.
As_IN required_VBN by_IN FRS_NNP 10_CD ,_, this_DT matter_NN will_MD be_VB kept_VBN under_IN review_NN and_CC SLAM_NNP technology_NN will_MD be_VB subject_JJ to_TO an_DT annual_JJ impairment_NN review_NN ._.
In_IN July_NNP 2002_CD ,_, the_DT Group_NNP announced_VBD that_IN it_PRP had_VBD entered_VBN into_IN arrangements_NNS with_IN Pharmacia_NNP now_RB part_NN of_IN Pfizer_NNP to_TO access_VB its_PRP$ product_NN Dipentum_NNP in_IN the_DT US_NNP and_CC European_JJ markets_NNS ._.
The_DT European_JJ product_NN rights_NNS were_VBD acquired_VBN outright_RB for_IN $_$ 20_CD million_CD ._.
The_DT US_NNP agreement_NN provided_VBD Celltech_NNP with_IN exclusive_JJ sales_NNS ,_, marketing_NN and_CC distribution_NN rights_NNS until_IN January_NNP 2005_CD ,_, at_IN which_WDT time_NN Celltech_NNP can_MD acquire_VB the_DT product_NN outright_RB at_IN its_PRP$ option_NN for_IN $_$ 5_CD million_CD ._.
The_DT substance_NN of_IN the_DT US_NNP transaction_NN is_VBZ that_IN of_IN an_DT outright_JJ acquisition_NN settled_VBD through_IN a_DT series_NN of_IN payments_NNS which_WDT are_VBP capital_NN in_IN nature_NN over_IN the_DT period_NN to_TO January_NNP 2005_CD ,_, followed_VBN by_IN the_DT $_$ 5_CD million_CD exercise_NN element_NN ._.
In_IN accordance_NN with_IN FRS_NNP 5_CD ,_, Reporting_NNP the_DT Substance_NNP of_IN Transactions_NNS ,_, the_DT Group_NNP has_VBZ capitalized_VBN the_DT total_NN of_IN these_DT payments_NNS of_IN $_$ 35.4_CD million_CD ._.
The_DT total_JJ capitalized_JJ for_IN the_DT European_JJ and_CC US_NNP rights_NNS is_VBZ thus_RB $_$ 55.4_CD million_CD 35.3_CD million_CD ._.
The_DT total_JJ capital_NN payments_NNS made_VBN during_IN 2003_CD amounted_VBD to_TO 11.7_CD million_CD ._.
The_DT Dipentum_NNP asset_NN is_VBZ being_VBG amortised_VBN over_IN 15_CD years_NNS ,_, which_WDT is_VBZ based_VBN on_IN the_DT Directors_NNS estimate_NN of_IN the_DT products_NNS useful_JJ economic_JJ life_NN ._.
In_IN estimating_VBG the_DT useful_JJ life_NN the_DT Directors_NNS have_VBP had_VBN regard_NN to_TO market_NN projections_NNS ,_, barriers_NNS to_TO entry_NN and_CC risk_NN of_IN generic_JJ products_NNS and_CC substitutes_NNS ._.
Dipentum_NNP sales_NNS recorded_VBN by_IN the_DT Group_NNP in_IN 2003_CD are_VBP 17.1_CD million_CD 2002_CD :_: 4.6_CD million_CD part_NN year_NN only_RB ._.
The_DT Group_NNP has_VBZ assets_NNS in_IN the_DT course_NN of_IN construction_NN or_CC commissioning_VBG which_WDT are_VBP not_RB depreciated_VBN of_IN 9.6_CD million_CD 2002_CD :_: 18.4_CD million_CD ._.
Of_IN the_DT 9.6_CD million_CD ,_, 6.2_CD million_CD are_VBP included_VBN within_IN the_DT long_JJ leasehold_NN category_NN and_CC 3.4_CD million_CD are_VBP within_IN plant_NN and_CC machinery_NN ._.
The_DT assets_NNS in_IN the_DT course_NN of_IN construction_NN relate_VBP primarily_RB to_TO the_DT expansion_NN of_IN the_DT laboratory_NN facilities_NNS at_IN Slough_NNP and_CC an_DT upgrade_NN to_TO the_DT manufacturing_NN facility_NN at_IN Ashton_NNP ._.
Capital_NNP expenditure_NN of_IN 16.2_CD million_CD in_IN the_DT year_NN took_VBD place_NN principally_RB on_IN the_DT UK_NNP Research_NNP and_CC Development_NNP facilities_NNS based_VBN in_IN Slough_NNP 7.7_CD million_CD ,_, the_DT Ashton_NNP manufacturing_NN site_NN 1.3_CD million_CD and_CC the_DT Rochester_NNP manufacturing_NN site_NN 3.1_CD million_CD ._.
The_DT freehold_JJ land_NN and_CC building_NN addition_NN of_IN $_$ 2_CD million_CD 1.1_CD million_CD relates_VBZ to_TO the_DT property_NN acquired_VBN from_IN Dr_NNP Ando_NNP in_IN a_DT related_JJ party_NN transaction_NN note_NN 25_CD ._.
Of_IN the_DT total_JJ expenditure_NN of_IN 16.2_CD million_CD ,_, 1.2_CD million_CD was_VBD accrued_VBN at_IN the_DT year_NN end_NN relating_VBG to_TO spend_VB at_IN Slough_NNP and_CC Ashton_NNP ._.
Transfers_NNS relate_VBP to_TO certain_JJ assets_NNS in_IN the_DT course_NN of_IN construction_NN which_WDT were_VBD initially_RB capitalized_VBN within_IN freehold_NN buildings_NNS ,_, but_CC which_WDT have_VBP been_VBN transferred_VBN to_TO plant_NN and_CC machinery_NN once_RB commissioned_VBN ._.
On_IN the_DT disposal_NN of_IN fixed_JJ assets_NNS no_DT material_NN profit_NN nor_CC loss_NN arose_VBD ._.
Investments_NNP Long-term_JJ investments_NNS Group_NNP Company_NNP 2003 2002 2003 2002_CD m_FW m_FW m_FW m_FW Loan_NN notes_VBZ 1.9_CD 32.9_CD Investment_NN in_IN Neogenesis_NNP 7.0_CD Investment_NN in_IN OGS_NNP 107.3_CD Investments_NNP in_IN subsidiary_NN undertakings_NNS 199.3_CD 199.3_CD Loans_NNS to_TO subsidiary_NN undertakings_NNS 4.3_CD 93.6_CD Own_NNP shares_NNS held_VBD 0.9_CD 0.3_CD 0.6_CD At_IN 31_CD December_NNP 2003_CD 2.8_CD 40.2_CD 311.5_CD 292.9_CD The_DT Company_NN investment_NN in_IN OGS_NNP of_IN 107.3_CD million_CD reflects_VBZ a_DT receipt_NN of_IN 1.2_CD million_CD in_IN cash_NN in_IN respect_NN of_IN share_NN options_NNS received_VBN in_IN OGS_NNP ._.
The_DT net_JJ figure_NN of_IN 106.1_CD million_CD is_VBZ the_DT Group_NNP investment_NN in_IN OGS_NNP as_IN shown_VBN in_IN note_NN 22_CD ._.
Loans_NNS to_TO subsidiary_NN undertakings_NNS have_VBP been_VBN subordinated_VBN by_IN Celltech_NNP Group_NNP plc_NN in_IN favor_NN of_IN any_DT third_JJ party_NN liabilities_NNS that_WDT may_MD accrue_VB ._.
Celltech_NNP Annual_JJ Report_NNP 2003_CD 61_CD Notes_NNS to_TO the_DT Financial_NNP Statements_NNP continued_VBD 13_CD ._.
Investments_NNP continued_VBD Movements_NNP in_IN investments_NNS during_IN the_DT year_NN are_VBP as_IN follows_VBZ :_: Group_NNP Company_NNP m_FW m_FW At_IN 1_CD January_NNP 2003_CD 40.2_CD 292.9_CD PowderJect_NNP loan_NN notes_NNS repaid_VBN 31.0_CD Acquisition_NNP of_IN own_JJ shares_NNS 1.4_CD 1.4_CD Accrual_NNP for_IN deferred_VBN bonus_NN scheme_NN 0.8_CD 0.8_CD Write-down_NN of_IN Neogenesis_NNP investment_NN 7.0_CD Movement_NNP in_IN loans_NNS to_TO subsidiary_NN undertakings_NNS 89.3_CD Acquisition_NNP of_IN OGS_NNP 107.3_CD At_IN 31_CD December_NNP 2003_CD 2.8_CD 311.5_CD ESOPs_NNP Employee_NNP share_NN schemes_NNS set_VBN up_RP as_IN trusts_NNS hold_VBP Celltech_NNP Group_NNP plc_NN ordinary_JJ shares_NNS to_TO meet_VB potential_JJ obligations_NNS under_IN the_DT schemes_NNS ._.
Options_NNS are_VBP satisfied_VBN by_IN the_DT transfer_NN of_IN shares_NNS held_VBN in_IN trust_NN where_WRB newly_RB issued_VBN shares_NNS are_VBP not_RB used_VBN ._.
The_DT Chiroscience_NNP 1994_CD Share_NN Ownership_NN Plan_NNP Trust_NNP holds_VBZ 255,346_CD shares_NNS at_IN 31_CD December_NNP 2003_CD ,_, of_IN which_WDT 43,806_CD are_VBP to_TO meet_VB options_NNS vested_VBN but_CC not_RB yet_RB exercised_VBN under_IN the_DT Chiroscience_NNP 1997_CD All_DT Employee_NNP Share_NN Option_NN Scheme_NN ._.
It_PRP is_VBZ the_DT Groups_NNS intention_NN that_IN the_DT shares_NNS over_IN and_CC above_IN those_DT required_VBN to_TO meet_VB the_DT 43,806_CD granted_VBN and_CC vested_VBN options_NNS will_MD be_VB used_VBN to_TO meet_VB obligations_NNS under_IN other_JJ schemes_NNS in_IN the_DT future_NN ._.
On_IN 13_CD January_NNP 2003_CD ,_, the_DT Celltech_NNP Group_NNP Employee_NNP Share_NNP Trust_NNP purchased_VBD 400,000_CD shares_NNS with_IN funds_NNS gifted_JJ by_IN Celltech_NNP Group_NNP plc._NN ._.
At_IN the_DT year_NN end_NN the_DT Celltech_NNP Group_NNP Employee_NNP Share_NNP Trust_NNP holds_VBZ 551,756_CD shares_NNS ,_, of_IN which_WDT 77,718_CD are_VBP to_TO meet_VB options_NNS granted_VBN under_IN the_DT Deferred_NNP Bonus_NNP Plan_NNP which_WDT have_VBP not_RB been_VBN exercised_VBN but_CC have_VBP vested_VBN ,_, and_CC 377,632_CD which_WDT have_VBP not_RB yet_RB vested_VBN ._.
The_DT book_NN value_NN of_IN all_DT Company_NN shares_NNS held_VBN in_IN trust_NN has_VBZ been_VBN written_VBN down_RP by_IN 0.3_CD million_CD ,_, being_VBG the_DT cost_NN of_IN shares_NNS over_IN which_WDT options_NNS have_VBP vested_VBN ._.
The_DT cost_NN of_IN shares_NNS over_IN which_WDT options_NNS have_VBP been_VBN granted_VBN but_CC not_RB vested_VBN at_IN 31_CD December_NNP 2003_CD is_VBZ accrued_VBN over_IN the_DT period_NN to_TO vesting_VBG ._.
At_IN the_DT year_NN end_NN the_DT accrual_NN is_VBZ 0.5_CD million_CD ._.
In_IN total_JJ ,_, the_DT amount_NN accrued_VBN or_CC written_VBN down_RP is_VBZ 0.8_CD million_CD ,_, as_IN shown_VBN in_IN the_DT table_NN above_IN ._.
The_DT total_JJ market_NN value_NN of_IN the_DT Companys_NNP shares_NNS held_VBD in_IN trust_NN at_IN 31_CD December_NNP 2003_CD is_VBZ 3.1_CD million_CD ,_, based_VBN on_IN the_DT year-end_JJ price_NN of_IN 3.78_CD ._.
Other_JJ investments_NNS As_IN at_IN 31_CD December_NNP 2003_CD ,_, the_DT Group_NNP has_VBZ one_CD remaining_VBG loan_NN note_NN due_RB from_IN Tillotts_NNPS Pharma_NNP AG_NNP ._.
This_DT loan_NN note_NN was_VBD issued_VBN to_TO Medeva_NNP PLC_NNP on_IN 26_CD April_NNP 1999_CD ._.
The_DT loan_NN note_NN bears_VBZ interest_NN at_IN 4_CD %_NN per_IN annum_NN and_CC is_VBZ repayable_JJ in_IN annual_JJ instalments_NNS dependent_JJ on_IN the_DT underlying_VBG adjusted_JJ profits_NNS of_IN Tillotts_NNP Pharma_NNP AG_NNP ,_, or_CC at_IN the_DT latest_JJS by_IN 31_CD December_NNP 2011_CD ._.
In_IN 2001_CD ,_, Celltech_NNP acquired_VBD a_DT minority_NN interest_NN in_IN Neogenesis_NNP for_IN $_$ 10_CD million_CD 7.0_CD million_CD ._.
With_IN the_DT acquisition_NN of_IN OGS_NNP the_DT Group_NNP inherited_VBD a_DT further_JJ 4.3_CD million_CD stake_NN in_IN Neogenesis_NNP ._.
The_DT total_JJ investment_NN has_VBZ been_VBN written_VBN down_RP to_TO nil_VB as_RB at_IN 31_CD December_NNP 2003_CD ,_, based_VBN on_IN the_DT expected_VBN realisable_JJ value_NN ._.
This_DT is_VBZ due_JJ to_TO the_DT shareholder_NN structure_NN which_WDT allows_VBZ series_NN A-D_NNP shareholders_NNS to_TO recover_VB their_PRP$ investment_NN before_IN series_NN E_NNP investors_NNS ._.
Both_DT the_DT initial_JJ Celltech_NNP holding_NN and_CC that_IN inherited_VBN with_IN OGS_NNP are_VBP part_NN of_IN the_DT series_NN E_NNP shares_NNS ._.
Celltech_NNP and_CC other_JJ series_NN E_NNP shareholders_NNS would_MD only_RB recover_VB their_PRP$ investment_NN if_IN the_DT sales_NNS proceeds_NNS of_IN Neogenesis_NNP exceeded_VBD $_$ 33.0_CD million_CD ._.
For_IN the_DT reasons_NNS set_VBN out_RP in_IN note_NN 5_CD ,_, the_DT Celltech_NNP Directors_NNS do_VBP not_RB consider_VB this_DT likely_JJ ._.
The_DT existing_VBG Celltech_NNP holding_NN has_VBZ been_VBN charged_VBN as_IN an_DT exceptional_JJ item_NN in_IN the_DT period_NN ,_, whereas_IN the_DT OGS_NNP holding_NN was_VBD written_VBN off_RP as_IN a_DT fair_JJ value_NN adjustment_NN to_TO the_DT acquired_VBN assets_NNS of_IN that_DT company_NN ._.
Investments_NNP continued_VBD The_DT following_VBG information_NN relates_VBZ to_TO the_DT Companys_NNPS principal_JJ subsidiary_NN undertakings_NNS Proportion_NNP held_VBD at_IN Country_NN of_IN 31_CD December_NNP Name_NN of_IN Company_NN incorporation_NN Holding_VBG 2003_CD Nature_NN of_IN Business_NNP Celltech_NNP R&D_NNP Limited_NNP England_NNP Ordinary_NNP shares_NNS 100_CD %_NN Darwin_NNP Discovery_NNP Limited_NNP England_NNP Ordinary_NNP shares_NNS 100_CD %_NN Chiroscience_NNP R&D_NNP Limited_NNP England_NNP Ordinary_NNP shares_NNS 100_CD %_NN Oxford_NNP GlycoSciences_NNP UK_NNP Limited_NNP England_NNP Ordinary_NNP shares_NNS 100_CD %_NN Research_NN and_CC Development_NNP Confirmant_NNP Limited_NNP England_NNP Ordinary_NNP shares_NNS 100_CD %_NN Celltech_NNP R&D_NNP Inc_NNP USA_NNP Common_NNP stock_NN 100_CD %_NN Cistron_NNP Biotechnology_NNP ,_, Inc_NNP USA_NNP Common_NNP stock_NN 100_CD %_NN Darwin_NNP Molecular_NNP Corporation_NNP USA_NNP Common_NNP stock_NN 100_CD %_NN Holding_VBG company_NN Oxford_NNP GlycoSciences_NNP Limited_NNP England_NNP Ordinary_NNP shares_NNS 100_CD %_NN Celltech_NNP Pharma_NNP GmbH_NNP &_CC Co_NNP KG_NNP Germany_NNP Ordinary_NNP shares_NNS 100_CD %_NN Celltech_NNP Pharmaceuticals_NNP Limited_NNP England_NNP Ordinary_NNP shares_NNS 100_CD %_NN Celltech_NNP Manufacturing_NNP Services_NNP Limited_NNP England_NNP Ordinary_NNP shares_NNS 100_CD %_NN International_NNP Medication_NNP Systems_NNPS UK_NNP Limited_NNP England_NNP Ordinary_NNP shares_NNS 100_CD %_NN Manufacture_NN and_CC sale_NN of_IN a_DT range_NN Celltech_NNP Pharma_NNP SA_NNP Spain_NNP Ordinary_NNP shares_NNS 100_CD %_NN of_IN branded_JJ specialty_NN and_CC generic_JJ Celltech_NNP Pharma_NNP SA_NNP France_NNP Ordinary_NNP shares_NNS 100_CD %_NN pharmaceutical_JJ products_NNS Celltech_NNP Pharma_NNP SA_NNP Belgium_NNP Ordinary_NNP shares_NNS 100_CD %_NN Celltech_NNP Nordic_NNP ApS_NNP Denmark_NNP Common_NNP stock_NN 100_CD %_NN Medeva_NNP Pharma_NNP Schweiz_NNP AG_NNP Switzerland_NNP Ordinary_NNP shares_NNS 100_CD %_NN Owns_VBZ intellectual_JJ property_NN relating_VBG to_TO pharmaceutical_JJ products_NNS Celltech_NNP Manufacturing_NNP CA_NNP ,_, Inc_NNP USA_NNP Common_NNP stock_NN 100_CD %_NN Celltech_NNP Pharmaceuticals_NNP ,_, Inc_NNP USA_NNP Common_NNP stock_NN 100_CD %_NN Manufacture_NN and_CC sale_NN of_IN a_DT range_NN of_IN Celltech_NNP Manufacturing_NNP ,_, Inc_NNP USA_NNP Common_NNP stock_NN 100_CD %_NN branded_VBD specialty_NN and_CC generic_JJ Upstate_NNP Pharma_NNP ,_, LLC_NNP USA_NNP Common_NNP stock_NN 100_CD %_NN pharmaceutical_JJ products_NNS Celltech_NNP Technologies_NNPS ,_, Inc_NNP USA_NNP Common_NNP stock_NN 100_CD %_NN Leasing_NNP operations_NNS Celltech_NNP US_NNP ,_, Inc_NNP USA_NNP Common_NNP stock_NN 100_CD %_NN Holding_VBG companies_NNS Celltech_NNP Holdings_NNPS ,_, Inc_NNP USA_NNP Common_NNP stock_NN 100_CD %_NN Celltech_NNP Pharma_NNP Europe_NNP Limited_NNP England_NNP Ordinary_NNP shares_NNS 100_CD %_NN Holding_VBG company_NN Owns_VBZ licences_NNS and_CC other_JJ intellectual_JJ property_NN relating_VBG to_TO pharmaceutical_JJ products_NNS Medeva_NNP Limited_NNP England_NNP Ordinary_NNP shares_NNS 100_CD %_NN Holding_VBG company_NN Celltech_NNP Limited_NNP England_NNP Ordinary_NNP shares_NNS 100_CD %_NN Treasury_NNP operations_NNS Celltech_NNP Reinsurance_NNP Ireland_NNP Limited_NNP Ireland_NNP Common_NNP stock_NN 100_CD %_NN Insurance_NN operations_NNS Celltech_NNP Insurance_NNP Ireland_NNP Limited_NNP Ireland_NNP Common_NNP stock_NN 100_CD %_NN Directly_RB held_VBD A_DT full_JJ list_NN of_IN subsidiaries_NNS will_MD be_VB annexed_VBN to_TO the_DT Companys_NNPS next_JJ annual_JJ return_NN filed_VBN with_IN the_DT Registrar_NNP of_IN Companies_NNS ._.
Stock_NNP Group_NNP 2003_CD 2002_CD m_NN m_NN Raw_NNP materials_NNS and_CC consumables_VBZ 6.1_CD 5.8_CD Clinical_JJ trials_NNS material_NN 2.7_CD 7.9_CD Work_NN in_IN progress_NN 7.7_CD 10.6_CD Finished_VBN goods_NNS and_CC goods_NNS for_IN resale_NN 19.9_CD 19.1_CD Total_JJ 36.4_CD 43.4_CD The_DT clinical_JJ trials_NNS material_NN amount_NN comprises_VBZ 2.5_CD million_CD 2002_CD :_: nil_NN of_IN CDP484_CD stock_NN and_CC 0.2_CD million_CD 2002_CD :_: 0.4_CD million_CD of_IN other_JJ materials_NNS ._.
During_IN the_DT year_NN ,_, the_DT Group_NNP wrote_VBD off_RP 7.5_CD million_CD of_IN CDP571_CD stocks_NNS which_WDT were_VBD held_VBN at_IN 31_CD December_NNP 2002_CD ._.
Celltech_NNP Annual_JJ Report_NNP 2003_CD 63_CD Notes_NNS to_TO the_DT Financial_NNP Statements_NNP continued_VBD 15_CD ._.
Debtors_NNP Group_NNP 2003_CD 2002_CD m_NN m_NN Trade_NNP debtors_NNS 43.7_CD 50.0_CD Other_JJ debtors_NNS 10.3_CD 13.7_CD Prepayments_NNS and_CC accrued_VBN income_NN 23.5_CD 12.9_CD Total_JJ 77.5_CD 76.6_CD Debtors_NNS include_VBP 9.3_CD million_CD 2002_CD :_: 5.9_CD million_CD which_WDT is_VBZ recoverable_JJ in_IN more_JJR than_IN one_CD year_NN ._.
Equity_NNP investments_NNS Group_NNP 2003_CD Dec_NNP 2002_CD m_NN m_NN Equity_NN investments_NNS 0.8_CD The_DT equity_NN investments_NNS held_VBN at_IN 31_CD December_NNP 2003_CD relate_VBP to_TO 1.3_CD million_CD shares_NNS held_VBN in_IN BioInvent_NNP ,_, a_DT company_NN listed_VBN on_IN the_DT Danish_JJ stock_NN market_NN ._.
The_DT investment_NN was_VBD inherited_VBN as_IN part_NN of_IN the_DT OGS_NNP acquisition_NN ._.
The_DT market_NN value_NN of_IN the_DT Groups_NNS holding_VBG as_RB at_IN 31_CD December_NNP 2003_CD was_VBD 1.1_CD million_CD ._.
During_IN 2002_CD ,_, the_DT Group_NNP completed_VBD the_DT process_NN of_IN disposing_VBG of_IN the_DT equity_NN investments_NNS which_WDT had_VBD been_VBN inherited_VBN as_IN part_NN of_IN the_DT Medeva_NNP acquisition_NN and_CC which_WDT had_VBD been_VBN held_VBN by_IN that_DT company_NN due_JJ to_TO its_PRP$ research_NN and_CC development_NN relationships_NNS ._.
In_IN total_JJ during_IN 2002_CD the_DT Group_NNP disposed_VBD of_IN 937,000_CD shares_NNS in_IN Targeted_NNP Genetics_NNP Corporation_NNP and_CC 207,500_CD shares_NNS in_IN Matrix_NNP Pharmaceuticals_NNP Inc._NNP ._.
The_DT disposals_NNS generated_VBD cash_NN of_IN 1.1_CD million_CD and_CC resulted_VBD in_IN a_DT loss_NN of_IN 0.9_CD million_CD which_WDT was_VBD recorded_VBN within_IN research_NN and_CC development_NN expenditure_NN ._.
Cash_NN and_CC liquid_JJ resources_NNS Celltech_NNP manages_VBZ its_PRP$ funds_NNS in_IN a_DT portfolio_NN of_IN cash_NN ,_, short-term_JJ bank_NN deposits_NNS and_CC liquid_JJ resources_NNS ,_, with_IN maturities_NNS chosen_VBN to_TO meet_VB its_PRP$ shortand_JJ medium-term_JJ requirements_NNS ._.
The_DT liquid_JJ resources_NNS are_VBP in_IN fully_RB negotiable_JJ instruments_NNS ,_, including_VBG treasury_NN bills_NNS ,_, certificates_NNS of_IN deposit_NN ,_, bills_NNS of_IN exchange_NN and_CC commercial_JJ paper_NN ,_, and_CC are_VBP managed_VBN by_IN Royal_NNP London_NNP Cash_NNP Management_NNP and_CC Royal_NNP Bank_NNP of_IN Scotland_NNP ._.
Group_NNP Company_NNP 2003 2002 2003 2002_CD m_FW m_FW m_FW m_FW Cash_NN 38.5_CD 81.1_CD 0.2_CD 22.3_CD Liquid_NN resources_NNS 116.5_CD 24.0_CD 8.7_CD Total_JJ cash_NN and_CC liquid_JJ resources_NNS 155.0_CD 105.1_CD 8.9_CD 22.3_CD As_IN at_IN 31_CD December_NNP 2002_CD ,_, Celltech_NNP held_VBD within_IN cash_NN and_CC liquid_JJ resources_NNS 7.2_CD million_CD of_IN restricted_VBN funds_NNS in_IN respect_NN of_IN financing_VBG arrangements_NNS with_IN regard_NN to_TO the_DT self_NN insurance_NN of_IN methylphenidate_NN the_DT alternative_NN financing_NN arrangements_NNS ._.
Following_VBG termination_NN of_IN the_DT alternative_JJ financing_NN arrangements_NNS for_IN methylphenidate_NN during_IN 2003_CD ,_, the_DT Group_NNP received_VBD 2.7_CD million_CD in_IN respect_NN of_IN the_DT insurance_NN deposit_NN 2002_CD :_: 2.7_CD million_CD included_VBD as_IN a_DT liquid_JJ resource_NN ._.
This_DT amount_NN was_VBD returned_VBN to_TO the_DT Group_NNP net_NN of_IN interest_NN and_CC fees_NNS ._.
In_IN addition_NN ,_, an_DT amount_NN of_IN 4.5_CD million_CD has_VBZ been_VBN released_VBN from_IN a_DT segregated_VBN fund_NN previously_RB held_VBN in_IN the_DT name_NN of_IN the_DT Company_NN and_CC managed_VBN by_IN one_CD of_IN the_DT Groups_NNS fund_NN managers_NNS in_IN respect_NN of_IN the_DT alternative_JJ financing_NN arrangement_NN ._.
Creditors_NNS :_: amounts_NNS falling_VBG due_JJ within_IN one_CD year_NN Group_NNP 2003_CD 2002_CD m_NN m_NN Accruals_NNP and_CC deferred_JJ income_NN 69.6_CD 53.0_CD Trade_NNP creditors_NNS 32.6_CD 24.5_CD Sales_NNS rebates_NNS and_CC wholesaler_NN charge_NN backs_VBZ 29.6_CD 18.2_CD Other_JJ creditors_NNS 9.5_CD 15.7_CD Senior_JJ loan_NN notes_NNS 31.2_CD Deferred_JJ consideration_NN 5.3_CD 11.7_CD Leasing_NNP obligations_NNS 0.6_CD 0.8_CD Corporation_NNP taxes_NNS 2.7_CD 5.0_CD Total_JJ 149.9_CD 160.1_CD The_DT senior_JJ loan_NN notes_NNS were_VBD repaid_VBN on_IN 17_CD December_NNP 2003_CD ._.
They_PRP were_VBD unsecured_JJ and_CC carried_VBD a_DT fixed_VBN coupon_NN rate_NN of_IN 6.51_CD %_NN ._.
Creditors_NNS :_: amounts_NNS falling_VBG due_JJ after_IN more_JJR than_IN one_CD year_NN Group_NNP 2003_CD 2002_CD m_NN m_NN Deferred_JJ consideration_NN 2.8_CD 8.9_CD Other_JJ creditors_NNS 2.5_CD 2.9_CD Leasing_NNP obligations_NNS 0.4_CD 0.9_CD Total_JJ 5.7_CD 12.7_CD The_DT deferred_VBN consideration_NN amounts_NNS disclosed_VBN in_IN both_DT current_JJ and_CC long-term_JJ creditors_NNS for_IN 2003_CD and_CC 2002_CD relate_VBP to_TO the_DT amounts_NNS payable_JJ on_IN the_DT acquisition_NN of_IN the_DT rights_NNS to_TO Dipentum_NNP in_IN the_DT US_NNP and_CC Europe_NNP see_VBP note_NN 11_CD ._.
Other_JJ long-term_JJ creditors_NNS of_IN 2.5_CD million_CD 2002_CD :_: 2.9_CD million_CD relate_VBP to_TO pension_NN obligations_NNS in_IN the_DT US_NNP see_VB note_NN 27_CD ,_, Pension_NNP fund_NN deficit_NN ._.
Obligations_NNS under_IN finance_NN and_CC operating_VBG leases_NNS Group_NNP 2003_CD 2002_CD Finance_NNP leases_VBZ m_NN m_NN Amounts_NNS payable_JJ :_: Within_IN one_CD year_NN 0.6_CD 0.8_CD Between_IN two_CD and_CC five_CD years_NNS 0.5_CD 1.1_CD Less_RBR interest_NN element_NN 0.1_CD 0.2_CD Finance_NNP lease_NN obligations_NNS 1.0_CD 1.7_CD Operating_NN leases_VBZ The_DT Group_NNP has_VBZ annual_JJ commitments_NNS under_IN noncancellable_JJ operating_NN leases_NNS as_IN follows_VBZ :_: Land_NNP and_CC buildings_NNS Other_JJ 2003 2002 2003 2002_CD m_FW m_FW m_FW m_FW Operating_NN leases_NNS which_WDT expire_VBP :_: Within_IN one_CD year_NN 0.7_CD 0.8_CD 0.1_CD Between_IN two_CD and_CC five_CD years_NNS 0.5_CD 1.0_CD 0.6_CD 1.4_CD Over_IN five_CD years_NNS 4.6_CD 5.0_CD Total_JJ annual_JJ commitment_NN 5.8_CD 6.0_CD 1.4_CD 1.5_CD The_DT Company_NN has_VBZ no_DT commitments_NNS under_IN operating_NN or_CC finance_NN leases_NNS ._.
Celltech_NNP Annual_JJ Report_NNP 2003_CD 65_CD Notes_NNS to_TO the_DT Financial_NNP Statements_NNP continued_VBD 20_CD ._.
Provisions_NNS for_IN liabilities_NNS and_CC charges_NNS Restructuring_NNP ,_, Deferred_NNP tax_NN integration_NN and_CC other_JJ Noninsured_NNP claims_VBZ Fair_NNP value_NN Group_NNP note_NN 8_CD i_FW ii_FW iii_FW Total_JJ m_NN m_FW m_FW m_FW m_FW Balance_NN at_IN 1_CD January_NNP 2003_CD 57.3_CD 3.0_CD 2.9_CD 63.2_CD Profit_NN and_CC loss_NN account_NN credit_NN charge_NN 36.2_CD 20.0_CD 3.0_CD 13.2_CD On_IN OGS_NNP acquisition_NN 34.2_CD 34.2_CD Profit_NN and_CC loss_NN account_NN release_NN 0.2_CD 0.2_CD Utilised_VBN in_IN year_NN 11.0_CD 22.5_CD 33.5_CD Currency_NNP translation_NN 4.5_CD 4.5_CD Transferred_VBN from_IN to_TO creditors_NNS 3.7_CD 3.7_CD At_IN 31_CD December_NNP 2003_CD 20.3_CD 11.8_CD 5.9_CD 11.7_CD 49.7_CD i_FW The_DT remaining_VBG provision_NN relates_VBZ to_TO restructuring_VBG charges_NNS booked_VBN during_IN 2003_CD as_IN described_VBN in_IN note_NN 5_CD of_IN 11.3_CD million_CD ,_, along_IN with_IN other_JJ provisions_NNS of_IN 0.5_CD million_CD ._.
The_DT opening_NN provision_NN of_IN 3.0_CD million_CD included_VBD 2.0_CD million_CD relating_VBG to_TO ML_NNP Laboratories_NNPS see_VBP below_IN and_CC other_JJ provisions_NNS of_IN 1.0_CD million_CD ._.
The_DT profit_NN and_CC loss_NN account_NN charge_NN is_VBZ the_DT cash_NN element_NN of_IN the_DT exceptional_JJ items_NNS see_VBP note_NN 5_CD ._.
The_DT utilisation_NN is_VBZ the_DT spend_VBP on_IN exceptional_JJ items_NNS of_IN 8.9_CD million_CD ,_, along_IN with_IN 2.0_CD million_CD paid_VBN to_TO ML_NNP Laboratories_NNPS and_CC 0.1_CD million_CD of_IN other_JJ ._.
In_IN 2002_CD ,_, Celltech_NNP negotiated_VBD a_DT settlement_NN to_TO terminate_VB certain_JJ co-development_NN relationships_NNS with_IN Innovata_NNP Biomed_NNP ,_, a_DT subsidiary_NN of_IN ML_NNP Laboratories_NNPS which_WDT had_VBD been_VBN inherited_VBN with_IN the_DT Medeva_NNP acquisition_NN ._.
The_DT terms_NNS of_IN the_DT termination_NN included_VBD a_DT 4.0_CD million_CD payment_NN to_TO ML_NNP Laboratories_NNP of_IN which_WDT the_DT final_JJ 2.0_CD million_CD was_VBD paid_VBN in_IN January_NNP 2003_CD ._.
In_IN total_JJ ,_, the_DT settlement_NN of_IN this_DT liability_NN resulted_VBD in_IN a_DT credit_NN of_IN 3.1_CD million_CD to_TO the_DT Group_NNP profit_NN and_CC loss_NN account_VBP taken_VBN in_IN the_DT year_NN ended_VBD 31_CD December_NNP 2002_CD ._.
ii_FW Since_IN 20_CD September_NNP 2001_CD ,_, the_DT Group_NNP has_VBZ been_VBN required_VBN to_TO increase_VB its_PRP$ levels_NNS of_IN self_NN insurance_NN in_IN respect_NN of_IN methylphenidate_NN ._.
In_IN addition_NN ,_, the_DT Group_NNP has_VBZ decided_VBN to_TO retain_VB a_DT level_NN of_IN self_NN insurance_NN in_IN respect_NN of_IN all_DT product_NN liability_NN up_IN to_TO an_DT annual_JJ limit_NN of_IN $_$ 13.5_CD million_CD ,_, as_RB well_RB as_IN self_NN insurance_NN in_IN respect_NN of_IN methylphenidate_NN of_IN up_RB to_TO $_$ 20_CD million_CD ._.
Whilst_NNP no_DT methylphenidate_NN claims_NNS have_VBP been_VBN received_VBN since_IN 20_CD September_NNP 2001_CD ,_, as_RB at_IN 31_CD December_NNP 2003_CD the_DT Group_NNP has_VBZ provided_VBN 5.4_CD million_CD based_VBN on_IN an_DT external_JJ review_NN of_IN the_DT likely_JJ liability_NN associated_VBN with_IN incidents_NNS that_WDT may_MD arise_VB from_IN past_JJ sales_NNS of_IN methylphenidate_NN prior_RB to_TO 20_CD September_NNP 2003_CD and_CC across_IN all_DT products_NNS after_IN 19_CD September_NNP 2003_CD ._.
A_DT further_JJ 0.5_CD million_CD has_VBZ been_VBN provided_VBN for_IN product_NN recall_NN and_CC other_JJ liabilities_NNS for_IN which_WDT the_DT Group_NNP has_VBZ no_DT external_JJ insurance_NN ._.
iii_FW On_IN the_DT acquisition_NN of_IN OGS_NNP the_DT Group_NNP provided_VBD for_IN certain_JJ onerous_JJ obligations_NNS ._.
These_DT relate_VBP primarily_RB to_TO lease_VB obligations_NNS ,_, committed_JJ development_NN spend_VBP on_IN non-valuable_JJ projects_NNS and_CC other_JJ contractual_JJ obligations_NNS see_VBP note_NN 22_CD ._.
There_EX are_VBP no_DT provisions_NNS for_IN liabilities_NNS and_CC charges_NNS in_IN the_DT Company_NN ._.
Derivatives_NNS and_CC other_JJ financial_JJ instruments_NNS The_DT disclosures_NNS below_IN ,_, with_IN the_DT exception_NN of_IN currency_NN exposures_NNS ,_, exclude_VBP short-term_JJ debtors_NNS and_CC creditors_NNS where_WRB permissible_JJ under_IN FRS_NNP 13_CD ._.
The_DT following_VBG categories_NNS of_IN short-term_JJ creditor_NN are_VBP included_VBN below_IN :_: borrowing_NN and_CC leasing_NN obligations_NNS and_CC foreign_JJ currency_NN denominated_VBD deferred_VBN consideration_NN ._.
The_DT main_JJ risks_NNS arising_VBG from_IN the_DT Groups_NNS use_NN of_IN financial_JJ instruments_NNS and_CC the_DT strategy_NN for_IN managing_VBG these_DT are_VBP set_VBN out_RP below_IN :_: Interest_NN rate_NN risk_NN The_DT Group_NNP repaid_VBD the_DT private_JJ placement_NN fixed_VBN borrowings_NNS of_IN 31.2_CD million_CD US$_$ 50_CD million_CD in_IN December_NNP 2003_CD ._.
Liquidity_NN risk_NN The_DT Group_NNP ensures_VBZ that_IN it_PRP has_VBZ sufficient_JJ long-term_JJ funding_NN and_CC committed_JJ bank_NN facilities_NNS to_TO meet_VB foreseeable_JJ peak_NN borrowing_NN requirements_NNS ._.
As_IN at_IN 31_CD December_NNP 2003_CD the_DT Group_NNP had_VBD 75_CD million_CD of_IN committed_JJ facilities_NNS 2002_CD :_: 107.2_CD million_CD of_IN which_WDT 75_CD million_CD were_VBD undrawn_JJ 2002_CD :_: 76.0_CD million_CD see_VBP section_NN iv_NN of_IN note_NN below_IN ._.
Foreign_JJ currency_NN risk_NN Approximately_RB 23_CD %_NN 2002_CD :_: 50_CD %_NN of_IN the_DT Group_NNP net_JJ assets_NNS excluding_VBG goodwill_NN are_VBP in_IN the_DT US_NNP ._.
The_DT Group_NNP does_VBZ not_RB currently_RB actively_RB hedge_VB against_IN the_DT effect_NN of_IN exchange_NN rate_NN differences_NNS resulting_VBG from_IN the_DT translation_NN of_IN foreign_JJ currency_NN earnings_NNS ,_, but_CC does_VBZ ,_, where_WRB appropriate_JJ ,_, seek_VB to_TO hedge_VB significant_JJ transaction_NN exposures_NNS ,_, which_WDT includes_VBZ hedging_VBG material_NN surplus_NN balances_VBZ not_RB denominated_VBN in_IN the_DT functional_JJ currency_NN of_IN the_DT operating_VBG unit_NN ._.
The_DT Group_NNP uses_VBZ financial_JJ derivatives_NNS ,_, in_IN particular_JJ forward_JJ currency_NN contracts_NNS ,_, to_TO manage_VB the_DT financial_JJ risks_NNS associated_VBN with_IN the_DT Groups_NNS underlying_VBG business_NN activity_NN ._.
Derivatives_NNS and_CC other_JJ financial_JJ instruments_NNS continued_VBD Credit_NNP risk_NN A_DT large_JJ number_NN of_IN major_JJ international_JJ financial_JJ institutions_NNS are_VBP counterparties_NNS to_TO the_DT foreign_JJ exchange_NN contracts_NNS and_CC deposits_NNS transacted_VBN by_IN the_DT Group_NNP ._.
Counterparties_NNS for_IN such_JJ transactions_NNS entered_VBD into_IN during_IN the_DT year_NN have_VBP a_DT long-term_JJ credit_NN rating_NN of_IN A_DT or_CC better_JJR ._.
The_DT Group_NNP monitors_VBZ its_PRP$ credit_NN exposure_NN to_TO its_PRP$ counterparties_NNS ,_, together_RB with_IN their_PRP$ credit_NN ratings_NNS ,_, and_CC ,_, by_IN policy_NN ,_, limits_VBZ the_DT amount_NN of_IN agreements_NNS or_CC contracts_NNS it_PRP enters_VBZ into_IN with_IN any_DT one_CD party_NN ._.
The_DT notional_JJ amounts_NNS of_IN financial_JJ instruments_NNS used_VBN in_IN interest_NN rate_NN and_CC foreign_JJ exchange_NN management_NN do_VBP not_RB represent_VB the_DT credit_NN risk_NN arising_VBG through_IN the_DT use_NN of_IN these_DT instruments_NNS ._.
The_DT immediate_JJ credit_NN risk_NN of_IN these_DT instruments_NNS is_VBZ represented_VBN by_IN the_DT fair_JJ value_NN of_IN contracts_NNS with_IN a_DT positive_JJ value_NN ._.
Cash_NN at_IN bank_NN and_CC liquid_JJ resources_NNS principally_RB comprise_VBP money_NN market_NN deposits_NNS ,_, commercial_JJ paper_NN and_CC investments_NNS ._.
The_DT investments_NNS are_VBP with_IN counterparties_NNS having_VBG strong_JJ credit_NN ratings_NNS ._.
The_DT Group_NNP considers_VBZ the_DT possibility_NN of_IN material_JJ loss_NN in_IN the_DT event_NN of_IN non-performance_JJ by_IN a_DT financial_JJ counterparty_NN or_CC the_DT non-payment_NN of_IN an_DT account_NN receivable_NN to_TO be_VB unlikely_JJ ,_, other_JJ than_IN as_IN already_RB provided_VBN for_IN in_IN the_DT accounts_NNS ._.
i_FW Interest_NN rate_NN risk_NN At_IN fixed_VBN InterestGroup_NNP At_IN fixed_VBN InterestGroup_NNP interest_NN free_JJ Total_JJ interest_NN free_JJ Total_JJ 2003 2003 2003 2002_CD 2002_CD 2002_CD Interest_NN rate_NN risk_NN profile_NN of_IN financial_JJ liabilities_NNS m_VBP m_FW m_FW m_FW m_FW m_FW Sterling_NN 1.0_CD 1.0_CD 1.7_CD 1.7_CD US_NNP dollar_NN 10.6_CD 10.6_CD 31.2_CD 23.5_CD 54.7_CD Preference_NN shares_NNS 3.4_CD 2.4_CD 5.8_CD Total_JJ 1.0_CD 10.6_CD 11.6_CD 36.3_CD 25.9_CD 62.2_CD Weighted_VBN average_JJ Weighted_JJ average_JJ Weighted_JJ average_JJ Weighted_JJ average_JJ interest_NN rates_NNS period_NN for_IN which_WDT interest_NN rates_NNS period_NN for_IN which_WDT rates_NNS are_VBP fixed_VBN rates_NNS are_VBP fixed_VBN 2003 2003 2002 2002_CD Fixed_VBN rate_NN financial_JJ liabilities_NNS %_NN Months_NNS %_NN Months_NNS Sterling_NNP 6.7_CD 23_CD 6.7_CD 35_CD US_NNP dollars_NNS 6.5_CD 12_CD Preference_NN shares_NNS 6.9_CD 3_CD Total_JJ 6.7_CD 23_CD 6.6_CD 12_CD The_DT interest-free_JJ liabilities_NNS are_VBP in_IN relation_NN to_TO Dipentum_NNP deferred_VBN consideration_NN and_CC pension_NN obligations_NNS provided_VBN in_IN the_DT US_NNP ._.
The_DT Group_NNP has_VBZ no_DT floating_VBG rate_NN financial_JJ liabilities_NNS 2002_CD :_: nil_NN ._.
The_DT financial_JJ liabilities_NNS of_IN the_DT Group_NNP comprised_VBD :_: 2003_CD 2002_CD m_NN m_NN Borrowings_NNS 31.2_CD Finance_NNP leases_NNS 1.0_CD 1.7_CD Deferred_JJ consideration_NN 8.1_CD 20.6_CD Other_JJ creditors_NNS 2.5_CD 2.9_CD Preference_NN shares_NNS 5.8_CD Total_JJ 11.6_CD 62.2_CD At_IN fixed_VBN At_IN floating_VBG Interestinterest_NNP rates_NNS interest_NN rates_NNS free_JJ Total_JJ Interest_NN rate_NN risk_NN profile_NN of_IN financial_JJ assets_NNS m_VBP m_FW m_FW m_FW Sterling_NN 98.1_CD 5.6_CD 103.7_CD US_NNP dollar_NN 43.1_CD 3.7_CD 46.8_CD Euro_NNP 13.6_CD 13.6_CD Swiss_JJ francs_NNS 1.9_CD 0.2_CD 2.1_CD At_IN 31_CD December_NNP 2003_CD 1.9_CD 155.0_CD 9.3_CD 166.2_CD Sterling_NNP 31.0_CD 32.5_CD 1.9_CD 65.4_CD US_NNP Dollar_NNP 59.8_CD 11.0_CD 70.8_CD Euro_NNP 12.7_CD 12.7_CD Swiss_JJ francs_NNS 1.9_CD 0.1_CD 2.0_CD At_IN 31_CD December_NNP 2002_CD 32.9_CD 105.1_CD 12.9_CD 150.9_CD Celltech_NNP Annual_JJ Report_NNP 2003_CD 67_CD Notes_NNS to_TO the_DT Financial_NNP Statements_NNP continued_VBD 21_CD ._.
Derivatives_NNS and_CC other_JJ financial_JJ instruments_NNS continued_VBD Floating_VBG rate_NN financial_JJ assets_NNS comprise_VBP cash_NN deposits_NNS in_IN the_DT money_NN market_NN ,_, certificates_NNS of_IN deposit_NN and_CC commercial_JJ paper_NN ._.
These_DT include_VBP deposits_NNS where_WRB the_DT interest_NN rate_NN is_VBZ fixed_VBN until_IN maturity_NN but_CC ,_, as_IN the_DT original_JJ maturity_NN is_VBZ less_JJR than_IN one_CD year_NN ,_, they_PRP are_VBP classified_VBN as_IN floating_VBG rate_NN financial_JJ instruments_NNS ._.
Fixed_VBN rate_NN deposits_NNS comprise_VBP 1.9_CD million_CD 2002_CD :_: 32.9_CD million_CD of_IN convertible_JJ loan_NN notes_NNS see_VBP note_NN 13_CD for_IN duration_NN carrying_VBG a_DT weighted_JJ average_JJ interest_NN rate_NN to_TO maturity_NN of_IN 4_CD %_NN 2002_CD :_: 6.8_CD %_NN ._.
The_DT interest-free_JJ assets_NNS relate_VBP to_TO long-term_JJ debtors_NNS see_VBP note_NN 15_CD ._.
In_IN 2002_CD the_DT interest-free_JJ assets_NNS related_VBN to_TO the_DT investment_NN in_IN Neogenesis_NNP see_VBP note_NN 13_CD and_CC long-term_JJ debtors_NNS see_VBP note_NN 15_CD ._.
ii_FW Currency_NNP exposures_NNS The_DT table_NN below_IN shows_NNS the_DT Groups_NNS transactional_JJ currency_NN exposures_NNS that_WDT give_VBP rise_VB to_TO net_JJ currency_NN gains_NNS and_CC losses_NNS in_IN the_DT profit_NN and_CC loss_NN account_NN ._.
Such_JJ exposures_NNS comprise_VBP the_DT monetary_JJ assets_NNS and_CC liabilities_NNS of_IN the_DT Group_NNP that_WDT are_VBP not_RB denominated_VBN in_IN the_DT functional_JJ currency_NN of_IN the_DT operating_VBG unit_NN involved_VBN ._.
Net_JJ monetary_JJ assets_NNS liabilities_NNS US_PRP $_$ Euro_NNP Other_JJ Total_NNP m_FW m_FW m_FW m_FW At_IN 31_CD December_NNP 2003_CD 15.5_CD 4.1_CD 0.2_CD 11.6_CD At_IN 31_CD December_NNP 2002_CD 5.9_CD 6.8_CD 0.2_CD 0.7_CD iii_FW Maturity_NN of_IN financial_JJ liabilities_NNS The_DT maturity_NN profile_NN of_IN the_DT Groups_NNS financial_JJ liabilities_NNS as_IN at_IN 31_CD December_NNP 2003_CD was_VBD as_IN follows_VBZ :_: 2003_CD m_NN In_IN one_CD year_NN or_CC less_JJR 5.9_CD In_IN more_JJR than_IN one_CD year_NN but_CC not_RB more_JJR than_IN two_CD years_NNS 3.2_CD In_IN more_JJR than_IN five_CD years_NNS 2.5_CD Total_JJ 11.6_CD iv_NN Committed_VBN borrowing_NN facilities_NNS The_DT facilities_NNS available_JJ as_IN at_IN 31_CD December_NNP 2003_CD were_VBD as_IN follows_VBZ :_: Committed_VBN Undrawn_JJ 2003_CD 2003_CD m_NN m_NN Revolving_VBG credit_NN facility_NN 65.0_CD 65.0_CD Overdraft_NN facility_NN 10.0_CD 10.0_CD Total_JJ 75.0_CD 75.0_CD Expiring_NN in_IN less_JJR than_IN one_CD year_NN 10.0_CD 10.0_CD Expiring_VBG in_IN more_JJR than_IN one_CD year_NN but_CC not_RB more_JJR than_IN two_CD years_NNS 65.0_CD 65.0_CD The_DT committed_JJ bank_NN facility_NN is_VBZ subject_JJ to_TO certain_JJ financial_JJ covenants_NNS which_WDT are_VBP tested_VBN twice_RB annually_RB ._.
The_DT Group_NNP currently_RB has_VBZ no_DT reason_NN to_TO believe_VB that_IN it_PRP will_MD not_RB be_VB able_JJ to_TO continue_VB to_TO meet_VB the_DT requirements_NNS of_IN these_DT covenants_NNS ._.
The_DT undrawn_JJ revolving_JJ credit_NN facility_NN is_VBZ available_JJ until_IN December_NNP 2005_CD ._.
v_NN Fair_NN value_NN of_IN financial_JJ instruments_NNS Book_NN value_NN Fair_NNP value_NN 2003 2002 2003 2002_CD m_FW m_FW m_FW m_FW Primary_JJ financial_JJ instruments_NNS :_: Cash_NN and_CC short-term_JJ deposits_NNS 155.0_CD 105.1_CD 155.0_CD 105.1_CD Convertible_JJ loan_NN notes_VBZ 1.9_CD 32.9_CD 1.9_CD 32.9_CD Investment_NN in_IN Neogenesis_NNP 7.0_CD 7.0_CD Long-term_JJ debtors_NNS 9.3_CD 5.9_CD 9.3_CD 5.7_CD Other_JJ creditors_NNS 2.5_CD 2.9_CD 2.5_CD 2.9_CD Finance_NNP leases_NNS 1.0_CD 1.7_CD 1.0_CD 1.7_CD Senior_JJ loan_NN notes_NNS 31.2_CD 31.2_CD Deferred_JJ consideration_NN 8.1_CD 20.6_CD 8.1_CD 20.6_CD Equity_NN investments_NNS 0.8_CD 1.1_CD Derivative_JJ financial_JJ instruments_NNS forward_RB exchange_NN contracts_NNS 5.8_CD 8.8_CD Preference_NN shares_NNS 5.8_CD 6.7_CD Total_JJ 155.4_CD 88.7_CD 161.5_CD 96.4_CD 68_CD Celltech_NNP Annual_JJ Report_NNP 2003_CD 21_CD ._.
Derivatives_NNS and_CC other_JJ financial_JJ instruments_NNS continued_VBD Market_NN values_NNS have_VBP been_VBN used_VBN to_TO determine_VB the_DT fair_JJ value_NN of_IN short-term_JJ deposits_NNS ,_, equity_NN investments_NNS and_CC the_DT derivative_JJ financial_JJ instruments_NNS ._.
Neogenesis_NNP is_VBZ an_DT unlisted_JJ company_NN and_CC the_DT total_JJ investment_NN has_VBZ been_VBN written_VBN down_RP to_TO nil_VB as_RB at_IN 31_CD December_NNP 2003_CD see_VBP note_NN 13_CD ._.
The_DT market_NN value_NN of_IN the_DT Groups_NNS holding_VBG in_IN BioInvent_NNP as_IN at_IN 31_CD December_NNP 2003_CD is_VBZ 1.1_CD million_CD see_VBP note_NN 16_CD ._.
In_IN 2002_CD ,_, the_DT Groups_NNS share_VBP price_NN as_IN of_IN 31_CD December_NNP 2002_CD was_VBD used_VBN to_TO determine_VB the_DT fair_JJ value_NN of_IN the_DT preference_NN shares_NNS ._.
Other_JJ amounts_NNS are_VBP determined_VBN to_TO be_VB equal_JJ to_TO their_PRP$ book_NN values_NNS ._.
vi_FW Gains_NNS and_CC losses_NNS on_IN hedges_NNS No_DT financial_JJ instruments_NNS were_VBD held_VBN for_IN the_DT purposes_NNS of_IN dealing_VBG or_CC other_JJ financial_JJ instrument_NN trading_NN activities_NNS ._.
Gains_NNS and_CC losses_NNS on_IN instruments_NNS used_VBN for_IN hedging_VBG are_VBP not_RB recognized_VBN until_IN the_DT exposure_NN that_WDT is_VBZ being_VBG hedged_VBN is_VBZ itself_PRP recognized_VBN ._.
The_DT table_NN below_IN shows_NNS the_DT extent_NN to_TO which_WDT the_DT Group_NNP has_VBZ unrecognised_JJ gains_NNS on_IN financial_JJ instruments_NNS ._.
2003_CD 2002_CD m_NN m_NN Unrecognised_JJ gains_NNS at_IN 1_CD January_NNP 8.8_CD 1.9_CD Additional_JJ gains_NNS on_IN unrecognised_JJ positions_NNS at_IN 1_CD January_NNP recognized_VBN in_IN the_DT year_NN 1.7_CD 2.4_CD Total_JJ gains_NNS recognized_VBN in_IN the_DT year_NN 10.5_CD 3.7_CD Unrecognised_JJ gains_NNS in_IN the_DT year_NN on_IN hedges_NNS taken_VBN out_RP in_IN 2001_CD 3.2_CD Unrecognised_JJ gains_NNS in_IN the_DT year_NN on_IN hedges_NNS taken_VBN out_RP in_IN 2002_CD 5.0_CD Unrecognised_JJ gains_NNS in_IN the_DT year_NN on_IN hedges_NNS taken_VBN out_RP in_IN 2003_CD 5.8_CD Total_JJ unrecognised_JJ gains_NNS at_IN 31_CD December_NNP 5.8_CD 8.8_CD All_PDT the_DT unrecognised_JJ gains_NNS as_IN at_IN 31_CD December_NNP 2003_CD are_VBP expected_VBN to_TO be_VB recognized_VBN during_IN 2004_CD ._.
Acquisition_NNP of_IN subsidiary_NN undertakings_NNS OGS_NNP Fair_NNP value_NN On_IN 26_CD February_NNP 2003_CD ,_, Celltech_NNP announced_VBD the_DT terms_NNS of_IN a_DT Cash_NNP Offer_NN for_IN the_DT entire_JJ issued_VBN and_CC to_TO be_VB issued_VBN share_NN capital_NN of_IN OGS_NNP ._.
On_IN 11_CD April_NNP 2003_CD ,_, the_DT Board_NNP of_IN OGS_NNP recommended_VBD that_IN shareholders_NNS accept_VBP the_DT Offer_NN by_IN Celltech_NNP and_CC by_IN the_DT 14_CD April_NNP 2003_CD the_DT Group_NNP held_VBD more_JJR than_IN 50_CD %_NN of_IN the_DT shares_NNS of_IN the_DT entity_NN ._.
The_DT Offer_NN of_IN 1.82_CD for_IN each_DT OGS_NNP share_NN ,_, valued_VBN the_DT company_NN at_IN 102.3_CD million_CD 56_CD million_CD issued_VBN shares_NNS at_IN the_DT date_NN of_IN acquisition_NN ,_, plus_CC a_DT further_JJ 0.9_CD million_CD of_IN subsequent_JJ option_NN exercises_NNS at_IN 1.82_CD ,_, less_CC 1.2_CD million_CD in_IN option_NN receipts_NNS ._.
On_IN 4_CD June_NNP 2003_CD ,_, Celltech_NNP announced_VBD that_IN it_PRP had_VBD purchased_VBN or_CC received_VBN valid_JJ acceptances_NNS in_IN respect_NN of_IN 90.3_CD %_NN of_IN the_DT issued_VBN share_NN capital_NN of_IN OGS_NNP ,_, and_CC had_VBD commenced_VBN the_DT procedure_NN for_IN the_DT compulsory_JJ acquisition_NN of_IN the_DT remaining_VBG OGS_NNP shares_NNS ._.
On_IN 18_CD July_NNP 2003_CD ,_, the_DT process_NN was_VBD completed_VBN ,_, and_CC OGS_NNP was_VBD fide-listed_VBN from_IN the_DT London_NNP Stock_NNP Exchange_NNP on_IN 21_CD July_NNP 2003_CD ._.
The_DT total_JJ cost_NN of_IN the_DT OGS_NNP acquisition_NN was_VBD 106.1_CD million_CD which_WDT includes_VBZ 3.8_CD million_CD of_IN expenses_NNS ._.
The_DT assets_NNS and_CC liabilities_NNS of_IN OGS_NNP acquired_VBD are_VBP as_IN follows_VBZ :_: Business_NNP held_VBD Fair_NNP value_NN Total_JJ fair_JJ Book_NN value_NN for_IN resale_NN adjustments_NNS value_NN m_NN m_FW m_FW m_FW Fixed_VBN assets_NNS a_DT 13.6_CD 8.0_CD 5.6_CD Investments_NNP b_NN 11.3_CD 5.8_CD 4.7_CD 0.8_CD Stocks_NNS 0.2_CD 0.2_CD Debtors_NNS c_NN 9.4_CD 2.9_CD 2.9_CD 3.6_CD Cash_NN and_CC liquid_JJ resources_NNS 126.6_CD 126.6_CD Creditors_NNS d_SYM 8.5_CD 0.7_CD 3.5_CD 4.3_CD Provisions_NNS e_SYM 34.2_CD 34.2_CD Deferred_JJ income_NN 8.2_CD 8.2_CD Businesses_NNS held_VBN for_IN resale_NN and_CC acquisition_NN of_IN Confirmant_NNP f_SYM 8.0_CD 2.5_CD 5.5_CD Net_JJ assets_NNS acquired_VBN 144.4_CD 46.4_CD 98.0_CD Total_JJ consideration_NN 106.1_CD Goodwill_NNP 8.1_CD Fair_NNP value_NN adjustments_NNS have_VBP been_VBN made_VBN to_TO the_DT book_NN value_NN of_IN the_DT assets_NNS and_CC liabilities_NNS to_TO adjust_VB ,_, where_WRB applicable_JJ ,_, the_DT carrying_VBG value_NN of_IN certain_JJ assets_NNS and_CC liabilities_NNS ._.
The_DT above_JJ fair_JJ values_NNS are_VBP preliminary_JJ and_CC will_MD be_VB further_JJ reviewed_VBN based_VBN on_IN additional_JJ information_NN available_JJ at_IN 30_CD June_NNP 2004_CD and_CC 31_CD December_NNP 2004_CD ._.
Based_VBN on_IN the_DT preliminary_JJ fair_JJ value_NN ,_, 8.1_CD million_CD of_IN goodwill_NN arises_VBZ on_IN this_DT transaction_NN ._.
The_DT goodwill_NN has_VBZ been_VBN capitalized_VBN and_CC is_VBZ being_VBG amortised_VBN over_IN 10_CD years_NNS ,_, which_WDT is_VBZ based_VBN on_IN the_DT Directors_NNS estimate_NN of_IN useful_JJ economic_JJ life_NN ._.
Celltech_NNP Annual_JJ Report_NNP 2003_CD 69_CD Notes_NNS to_TO the_DT Financial_NNP Statements_NNP continued_VBD 22_CD ._.
Acquisition_NNP of_IN subsidiary_NN undertakings_NNS continued_VBD The_DT material_NN fair_JJ value_NN adjustments_NNS to_TO the_DT net_JJ assets_NNS of_IN OGS_NNP were_VBD determined_VBN as_IN follows_VBZ :_: a_DT Tangible_JJ fixed_JJ assets_NNS have_VBP been_VBN written_VBN off_RP ,_, as_IN they_PRP will_MD not_RB be_VB used_VBN by_IN Celltech_NNP and_CC recoverable_JJ values_NNS are_VBP considered_VBN to_TO be_VB negligible_JJ ._.
Intangible_JJ assets_NNS have_VBP not_RB been_VBN capitalized_VBN separately_RB from_IN goodwill_NN as_IN the_DT value_NN of_IN the_DT business_NN is_VBZ considered_VBN to_TO be_VB primarily_RB in_IN early-stage_JJ oncology_NN research_NN projects_NNS ._.
Celltech_NNP does_VBZ not_RB consider_VB that_IN a_DT reliable_JJ valuation_NN can_MD be_VB made_VBN of_IN such_JJ projects_NNS suitable_JJ for_IN capitalization_NN separate_JJ from_IN goodwill_NN ._.
b_NN Investments_NNPS have_VBP been_VBN written_VBN down_RP to_TO recoverable_JJ value_NN based_VBN on_IN market_NN value_NN and_CC have_VBP been_VBN classified_VBN on_IN the_DT Celltech_NNP balance_NN sheet_NN as_IN equity_NN investments_NNS ._.
OGS_NNP investments_NNS included_VBD a_DT 4.3_CD million_CD stake_NN in_IN Neogenesis_NNP which_WDT has_VBZ been_VBN written_VBN down_RP to_TO nil_VB see_VB notes_NNS 5_CD and_CC 13_CD ._.
c_NN Debtors_NNS have_VBP been_VBN written_VBN down_RP to_TO recoverable_JJ value_NN ._.
A_DT significant_JJ proportion_NN of_IN the_DT OGS_NNP debtors_NNS were_VBD prepayments_NNS for_IN activities_NNS and_CC projects_NNS which_WDT were_VBD discontinued_VBN by_IN Celltech_NNP ._.
Consequently_RB these_DT had_VBD no_DT value_NN to_TO Celltech_NNP ._.
d_LS OGS_NNP creditor_NN and_CC accrual_NN balances_NNS inherited_VBN were_VBD adjusted_VBN in_IN the_DT light_NN of_IN the_DT actual_JJ settlements_NNS made_VBD post-acquisition_JJ ._.
e_LS Fair_NNP value_NN provisions_NNS have_VBP been_VBN established_VBN for_IN onerous_JJ obligations_NNS inherited_VBN with_IN the_DT acquisition_NN ._.
These_DT relate_VBP primarily_RB to_TO lease_VB obligations_NNS ,_, committed_JJ development_NN spend_VBP on_IN non-valuable_JJ projects_NNS and_CC other_JJ contractual_JJ obligations_NNS ,_, including_VBG payments_NNS to_TO former_JJ senior_JJ executives_NNS who_WP had_VBD change_NN of_IN ownership_NN termination_NN clauses_NNS in_IN their_PRP$ service_NN contracts_NNS ._.
f_LS The_DT proteomics_NNS business_NN of_IN OGS_NNP was_VBD held_VBN for_IN resale_NN ._.
The_DT fair_JJ value_NN represents_VBZ the_DT estimated_JJ result_NN of_IN the_DT business_NN prior_RB to_TO any_DT disposal_NN together_RB with_IN the_DT anticipated_JJ net_JJ proceeds_NNS from_IN the_DT assets_NNS inherited_VBN ._.
The_DT table_NN below_IN sets_NNS out_IN the_DT material_NN balance_NN aggregated_VBN on_IN to_TO the_DT businesses_NNS held_VBN for_IN resale_NN line_NN on_IN acquisition_NN ._.
m_NN Net_NN receipt_NN from_IN termination_NN of_IN Confirmant_NNP Limited_NNP joint_JJ venture_NN see_VBP note_NN 23_CD 6.4_CD Other_JJ proteomics_NNS 0.9_CD Business_NN held_VBN for_IN resale_NN 5.5_CD At_IN the_DT half_NN year_NN ,_, the_DT businesses_NNS held_VBN for_IN resale_NN line_NN was_VBD reported_VBN as_IN being_VBG 8.0_CD million_CD ,_, the_DT adjusted_VBN fair_JJ value_NN at_IN 31_CD December_NNP 2003_CD reflects_VBZ the_DT unsuccessful_JJ outcome_NN of_IN efforts_NNS to_TO dispose_VB of_IN the_DT business_NN see_VB note_NN 23_CD ._.
Due_JJ to_TO the_DT businesses_NNS no_RB longer_RB being_VBG held_VBN for_IN disposal_NN as_IN at_IN 31_CD December_NNP 2003_CD the_DT remaining_VBG assets_NNS and_CC liabilities_NNS of_IN the_DT proteomics_NNS business_NN and_CC Confirmant_NNP Limited_NNP are_VBP included_VBN within_IN the_DT usual_JJ statutory_JJ headings_NNS ._.
Information_NN on_IN OGS_NNP pre-acquisition_JJ results_NNS The_DT last_JJ financial_JJ statements_NNS of_IN OGS_NNP were_VBD prepared_VBN for_IN the_DT year_NN to_TO 31_CD December_NNP 2002_CD ,_, and_CC were_VBD audited_VBN by_IN Ernst_NNP &_CC Young_NNP ._.
The_DT summarised_JJ profit_NN and_CC loss_NN account_NN and_CC statement_NN of_IN total_JJ recognized_VBN gains_NNS and_CC losses_NNS for_IN OGS_NNP for_IN the_DT period_NN from_IN 1_CD January_NNP 2003_CD to_TO the_DT end_NN of_IN April_NNP ,_, the_DT period_NN prior_RB to_TO the_DT effective_JJ date_NN of_IN acquisition_NN ,_, and_CC for_IN the_DT preceding_JJ year_NN are_VBP as_IN follows_VBZ :_: 1_CD Jan_NNP to_TO 30_CD Apr_NNP unaudited_JJ 31_CD Dec_NNP 2002_CD m_FW m_FW Turnover_NN 3.7_CD 14.0_CD Net_JJ operating_NN costs_NNS 16.8_CD 54.8_CD Operating_NN loss_NN 13.1_CD 40.8_CD Share_NN of_IN joint_JJ venture_NN loss_NN 1.6_CD 4.4_CD Interest_NN receivable_JJ 1.9_CD 6.4_CD Amount_NNP written_VBN off_RP investments_NNS 2.4_CD Loss_NN on_IN ordinary_JJ activities_NNS before_IN taxation_NN 12.8_CD 41.2_CD Tax_NNP on_IN loss_NN on_IN ordinary_JJ activities_NNS 3.3_CD Loss_NN on_IN ordinary_JJ net_JJ activities_NNS after_IN taxation_NN 12.8_CD 37.9_CD Due_JJ to_TO the_DT significant_JJ restructuring_NN undertaken_VBN on_IN OGS_NNP ,_, the_DT above_JJ results_NNS are_VBP not_RB indicative_JJ of_IN the_DT impact_NN of_IN the_DT acquisition_NN on_IN Celltechs_NNP result_NN ._.
The_DT turnover_NN and_CC operating_NN losses_NNS of_IN the_DT business_NN ,_, before_IN restructuring_NN and_CC goodwill_NN items_NNS ,_, consolidated_VBN by_IN the_DT Group_NNP for_IN the_DT period_NN since_IN acquisition_NN are_VBP nil_NN and_CC 3.9_CD million_CD respectively_RB ._.
In_IN addition_NN ,_, a_DT charge_NN of_IN 4.5_CD million_CD is_VBZ included_VBN within_IN exceptional_JJ items_NNS for_IN OGS_NNP in_IN respect_NN of_IN integration_NN and_CC products_NNS that_WDT are_VBP being_VBG discontinued_VBN ._.
Both_DT these_DT amounts_NNS are_VBP reflected_VBN in_IN the_DT cash_NN flow_NN analysis_NN of_IN the_DT impact_NN of_IN the_DT acquisition_NN of_IN OGS_NNP shown_VBN below_IN ._.
Acquisition_NNP of_IN subsidiary_NN undertakings_NNS continued_VBD Impact_NNP of_IN OGS_NNP acquisition_NN on_IN cash_NN flows_VBZ OGS_NNP contribution_NN to_TO the_DT Group_NNP cashflow_NN since_IN the_DT date_NN of_IN acquisition_NN can_MD be_VB summarised_VBN as_IN follows_VBZ :_: m_VB Operating_NN result_NN 3.9_CD million_CD operating_NN loss_NN ,_, integration_NN costs_NNS 4.5_CD million_CD 8.4_CD Cashflow_NNP on_IN fair_JJ value_NN provisions_NNS 22.5_CD Working_JJ capital_NN movements_NNS 4.4_CD Net_JJ cash_NN outflow_NN from_IN operating_VBG activities_NNS 35.3_CD Interest_NN received_VBD 2.1_CD Taxation_NNP 3.6_CD Cash_NN funding_NN in_IN respect_NN of_IN businesses_NNS held_VBN for_IN resale_NN 0.9_CD Cash_NN outflow_NN before_IN use_NN of_IN liquid_JJ resources_NNS 30.5_CD The_DT total_JJ impact_NN on_IN cash_NN and_CC liquid_JJ resources_NNS ,_, including_VBG acquisition_NN flows_NNS for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2003_CD but_CC excluding_VBG the_DT cost_NN of_IN continuing_VBG activities_NNS ,_, is_VBZ set_VBN out_RP below_IN :_: m_VB Cost_NN of_IN shares_NNS 102.3_CD Transaction_NN costs_VBZ 3.8_CD 106.1_CD Cash_NN and_CC liquid_JJ resources_NNS inherited_VBN with_IN OGS_NNP 126.6_CD Cash_NN outflow_NN since_IN date_NN of_IN acquisition_NN 30.5_CD Net_JJ Confirmant_JJ cash_NN acquired_VBD 6.4_CD Costs_NNS in_IN relation_NN to_TO continuing_VBG activities_NNS 3.9_CD Total_JJ inflow_NN for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2003_CD 0.3_CD 23_CD ._.
Businesses_NNS held_VBD for_IN resale_NN On_IN acquisition_NN of_IN OGS_NNP ,_, Celltech_NNP identified_VBD the_DT proteomics_NNS business_NN as_IN being_VBG held_VBN for_IN immediate_JJ disposal_NN ._.
After_IN significant_JJ initial_JJ interest_NN the_DT last_JJ potential_JJ buyer_NN for_IN the_DT proteomics_NNS business_NN withdrew_VBD from_IN negotiations_NNS in_IN late_JJ November_NNP 2003_CD ._.
At_IN that_DT point_NN ,_, a_DT decision_NN was_VBD taken_VBN to_TO terminate_VB the_DT operations_NNS immediately_RB ._.
Consequently_RB ,_, from_IN that_DT date_NN onwards_NNS ,_, it_PRP was_VBD no_RB longer_RB appropriate_JJ to_TO treat_VB the_DT business_NN as_IN a_DT business_NN held_VBD for_IN disposal_NN and_CC ,_, therefore_RB ,_, as_IN part_NN of_IN the_DT OGS_NNP closure_NN costs_VBZ a_DT charge_NN of_IN 0.5_CD million_CD was_VBD made_VBN in_IN respect_NN of_IN proteomics_NNS redundancies_NNS ._.
OGS_NNP was_VBD party_NN to_TO a_DT 50:50_CD joint_JJ venture_NN with_IN Marconi_NNP ,_, in_IN a_DT company_NN known_VBN as_IN Confirmant_NNP Limited_NNP Confirmant_NNP ._.
The_DT purpose_NN of_IN the_DT joint_JJ venture_NN was_VBD to_TO integrate_VB and_CC leverage_NN Marconis_NNP broadband_NN data_NNS transmission_NN capabilities_NNS with_IN OGS_NNP proteomics_NNS database_NN ._.
Confirmant_NNP had_VBD initial_JJ funding_NN of_IN 30_CD million_CD contributed_VBD equally_RB by_IN Marconi_NNP and_CC OGS_NNP ._.
Confirmant_JJ operated_VBN with_IN a_DT separate_JJ management_NN and_CC sales_NNS team_NN ._.
Following_VBG the_DT failure_NN to_TO dispose_VB of_IN the_DT proteomics_NNS business_NN ,_, agreement_NN was_VBD reached_VBN with_IN Marconi_NNP to_TO terminate_VB the_DT joint_JJ venture_NN and_CC distribute_VB the_DT remaining_VBG cash_NN ._.
This_DT resulted_VBD in_IN a_DT payment_NN to_TO Marconi_NNP of_IN 4.1_CD million_CD and_CC OGS_NNP then_RB acquired_VBD full_JJ rights_NNS over_IN the_DT remaining_VBG 10.5_CD million_CD of_IN cash_NN and_CC liquid_JJ resources_NNS within_IN Confirmant_NNP ._.
This_DT net_JJ 6.4_CD million_CD receipt_NN has_VBZ been_VBN included_VBN in_IN determining_VBG the_DT value_NN of_IN businesses_NNS held_VBN for_IN disposal_NN in_IN note_NN 22_CD above_IN ._.
The_DT payment_NN to_TO Marconi_NNP took_VBD account_NN of_IN amounts_NNS owed_VBN to_TO OGS_NNP and_CC its_PRP$ share_NN of_IN the_DT Confirmant_NNP closure_NN costs_NNS ._.
The_DT table_NN below_IN summarises_NNS the_DT transactions_NNS :_: m_VB Acquisition_NNP of_IN remaining_VBG 50_CD %_NN of_IN Confirmant_NNP 4.1_CD Cash_NNP acquired_VBD 10.5_CD Net_JJ cash_NN acquired_VBD 6.4_CD Celltech_NNP Annual_JJ Report_NNP 2003_CD 71_CD Notes_NNS to_TO the_DT Financial_NNP Statements_NNP continued_VBD 24_CD ._.
Shareholders_NNS funds_NNS Called_VBN up_RP Share_NN Profit_NN share_NN premium_NN Other_JJ and_CC loss_NN capital_NN account_NN reserves_NNS account_VBP Total_NNP Group_NNP m_FW m_FW m_FW m_FW m_FW At_IN 1_CD January_NNP 2003_CD 141.3_CD 83.3_CD 621.4_CD 281.6_CD 564.4_CD Preference_NN shares_NNS redeemed_VBN 3.5_CD 2.4_CD 5.9_CD Shares_NNS issued_VBN to_TO meet_VB redemption_NN 1.0_CD 4.9_CD 5.9_CD Proceeds_NNS of_IN exercise_NN of_IN Celltech_NNP share_NN options_NNS 0.3_CD 0.3_CD Currency_NNP translation_NN difference_NN on_IN foreign_JJ currency_NN net_JJ investments_NNS and_CC net_JJ borrowings_NNS 4.9_CD 4.9_CD Preference_NN share_NN dividends_NNS transferred_VBN to_TO other_JJ reserves_NNS 0.1_CD 0.1_CD Net_JJ transfer_NN to_TO profit_NN and_CC loss_NN account_NN 53.9_CD 53.9_CD At_IN 31_CD December_NNP 2003_CD 138.8_CD 88.5_CD 619.1_CD 340.5_CD 505.9_CD Other_JJ reserves_NNS arise_VBP from_IN the_DT reorganisation_NN of_IN the_DT Group_NNP structure_NN on_IN 1_CD October_NNP 1997_CD and_CC the_DT acquisitions_NNS of_IN Darwin_NNP Molecular_NNP Corporation_NNP ,_, Medeva_NNP and_CC Cistron_NNP ,_, together_RB with_IN merger_NN adjustments_NNS in_IN relation_NN to_TO the_DT merger_NN of_IN Celltech_NNP and_CC Chiroscience_NNP ,_, and_CC the_DT reserve_NN transfer_NN on_IN disposal_NN of_IN ChiroTech_NNP ._.
The_DT cumulative_JJ goodwill_NN written_VBN off_RP directly_RB to_TO reserves_NNS is_VBZ 60.5_CD million_CD 2002_CD :_: 60.5_CD million_CD ._.
Called_VBN up_RP Share_NN Profit_NN share_NN premium_NN Other_JJ and_CC loss_NN capital_NN account_NN reserves_NNS account_VBP Total_JJ Company_NN m_NN m_FW m_FW m_FW m_FW At_IN 1_CD January_NNP 2003_CD 141.3_CD 83.3_CD 2.4_CD 88.2_CD 315.2_CD Preference_NN shares_NNS redeemed_VBN 3.5_CD 2.4_CD 5.9_CD Issue_NN of_IN ordinary_JJ shares_NNS 1.0_CD 5.2_CD 6.2_CD Net_JJ transfer_NN from_IN profit_NN and_CC loss_NN account_NN 4.9_CD 4.9_CD At_IN 31_CD December_NNP 2003_CD 138.8_CD 88.5_CD 93.1_CD 320.4_CD Analysis_NN of_IN shareholders_NNS funds_NNS Group_NNP Company_NNP 2003 2002 2003 2002_CD m_FW m_FW m_FW m_FW Equity_NN interests_NNS 505.9_CD 558.6_CD 320.4_CD 309.4_CD Non-equity_NN interests_NNS 5.8_CD 5.8_CD Shareholders_NNS funds_NNS 505.9_CD 564.4_CD 320.4_CD 315.2_CD In_IN 2002_CD non-equity_JJ comprises_VBZ 6.9_CD %_NN convertible_JJ redeemable_JJ preference_NN shares_NNS and_CC accrued_VBN preference_NN share_NN dividends_NNS ._.
No_DT voting_NN rights_NNS were_VBD attached_VBN to_TO these_DT shares_NNS ._.
Analysis_NN of_IN share_NN capital_NN 2003_CD 2002_CD Authorised_NNP Number_NNP Number_NNP Ordinary_NNP shares_NNS of_IN 50p_JJ each_DT 373,064,416_CD 373,064,416_CD 6.9_CD %_NN convertible_JJ redeemable_JJ cumulative_JJ preference_NN shares_NNS of_IN 1_CD each_DT 3,467,790_CD 3,467,790_CD Allotted_NNP ,_, called_VBD up_RP and_CC fully_RB paid_VBN 2003 2002 2003 2002_CD Number_NNP Number_NNP m_FW m_FW Ordinary_NNP shares_NNS of_IN 50p_JJ each_DT 277,654,453_CD 275,527,304_CD 138.8_CD 137.9_CD 6.9_CD %_NN convertible_JJ redeemable_JJ cumulative_JJ preference_NN shares_NNS of_IN 1_CD each_DT 3,467,790_CD 3.4_CD Total_JJ 277,654,453_CD 278,995,094_CD 138.8_CD 141.3_CD During_IN the_DT period_NN ,_, 170,351_CD ordinary_JJ shares_NNS were_VBD issued_VBN and_CC fully_RB paid_VBN upon_IN the_DT exercise_NN of_IN share_NN options_NNS ._.
The_DT cash_NN consideration_NN received_VBD amounted_VBD to_TO 0.3_CD million_CD and_CC resulted_VBD in_IN an_DT increase_NN in_IN the_DT share_NN premium_NN account_NN of_IN 0.3_CD million_CD ._.
On_IN 31_CD March_NNP 2003_CD ,_, 3.5_CD million_CD convertible_JJ redeemable_JJ cumulative_JJ preference_NN shares_NNS were_VBD converted_VBN into_IN ordinary_JJ shares_NNS at_IN a_DT price_NN of_IN 3_CD per_IN share_NN ._.
In_IN addition_NN ,_, the_DT cumulative_JJ unpaid_JJ interest_NN accrual_NN of_IN 2.4_CD million_CD on_IN these_DT preference_NN shares_NNS was_VBD also_RB converted_VBN to_TO ordinary_JJ shares_NNS at_IN a_DT price_NN of_IN 3_CD per_IN share_NN ._.
In_IN total_JJ ,_, 1,956,798_CD new_JJ ordinary_JJ shares_NNS were_VBD issued_VBN on_IN the_DT conversion_NN of_IN the_DT preference_NN shares_NNS ,_, equating_VBG to_TO a_DT redemption_NN of_IN 5,870,394_CD of_IN preference_NN shares_NNS and_CC related_JJ interest_NN ._.
Shareholders_NNS funds_NNS continued_VBD Share_NN options_NNS outstanding_JJ to_TO employees_NNS of_IN the_DT Group_NNP as_IN at_IN 31_CD December_NNP 2003_CD are_VBP as_IN follows_VBZ :_: i_FW Celltech_NNP Executive_NNP Share_NNP Option_NN Schemes_NNS 1,856_CD employees_NNS hold_VBP options_NNS including_VBG unapproved_JJ options_NNS to_TO subscribe_VB for_IN up_RB to_TO 14,974,819_CD shares_NNS at_IN prices_NNS ranging_VBG between_IN 205p_CD and_CC 1295p_CD per_IN share_NN exercisable_JJ between_IN 2003_CD and_CC 2013_CD ._.
This_DT includes_VBZ both_DT Chiroscience_NNP and_CC Medeva_NNP originating_VBG Executive_NNP options_NNS ._.
Included_VBN in_IN this_DT figure_NN are_VBP 43,806_CD options_NNS held_VBN under_IN the_DT Chiroscience_NNP ESOP_NNP Trust_NNP ._.
ii_FW Celltech_NNP Savings_NNP Related_NNP Share_NNP Option_NN Schemes_NNS includes_VBZ Celltech_NNP ,_, Chiroscience_NNP and_CC Medeva_NNP originating_VBG schemes_NNS 947_CD employees_NNS hold_VBP options_NNS to_TO subscribe_VB for_IN up_RB to_TO 2,016,628_CD ordinary_JJ shares_NNS at_IN prices_NNS between_IN 237p_CD and_CC 948p_CD per_IN share_NN exercisable_JJ between_IN 2003_CD and_CC 2010_CD ._.
iii_FW Deferred_NNP Bonus_NNP Plan_NNP 13_CD employees_NNS hold_VBP options_NNS to_TO subscribe_VB for_IN up_RB to_TO 455,350_CD shares_NNS ._.
The_DT shares_NNS are_VBP issued_VBN and_CC are_VBP held_VBN in_IN the_DT Celltech_NNP Group_NNP plc_NN Employee_NNP Share_NNP Trust_NNP ._.
Related_VBN party_NN transaction_NN During_IN the_DT year_NN ,_, Celltech_NNP entered_VBD into_IN a_DT related_JJ party_NN transaction_NN with_IN its_PRP$ new_JJ Chief_NNP Executive_NNP ,_, Dr._NNP Gran_NNP Ando_NNP ._.
The_DT transaction_NN involved_VBD the_DT acquisition_NN by_IN Celltech_NNP on_IN 22_CD October_NNP 2003_CD of_IN Dr._NNP Andos_NNP home_NN in_IN Mendham_NNP Borough_NNP ,_, New_NNP Jersey_NNP ,_, USA_NNP ._.
The_DT purpose_NN of_IN the_DT transaction_NN was_VBD to_TO expedite_VB Dr._NNP Andos_NNP relocation_NN to_TO the_DT United_NNP Kingdom_NNP ._.
The_DT agreed_JJ acquisition_NN price_NN for_IN the_DT property_NN was_VBD $_$ 2_CD million_CD 1.1_CD million_CD which_WDT was_VBD based_VBN on_IN the_DT mid-point_NN of_IN two_CD independent_JJ valuations_NNS ._.
The_DT total_JJ cost_NN to_TO Celltech_NNP including_VBG acquisition-related_JJ expenditure_NN amounted_VBD to_TO $_$ 2,026,842_CD ._.
The_DT transaction_NN involved_VBN full_JJ transfer_NN of_IN the_DT rights_NNS to_TO the_DT property_NN to_TO Celltech_NNP :_: no_DT further_JJ amounts_NNS become_VBP payable_JJ to_TO or_CC from_IN Dr._NNP Ando_NNP ._.
Full_JJ settlement_NN of_IN the_DT amounts_NNS due_JJ to_TO Dr._NNP Ando_NNP was_VBD made_VBN on_IN 22_CD October_NNP 2003_CD ._.
As_IN at_IN 31_CD December_NNP 2003_CD the_DT property_NN is_VBZ still_RB held_VBN by_IN Celltech_NNP and_CC is_VBZ included_VBN within_IN freehold_NN tangible_JJ fixed_JJ assets_NNS ,_, see_VBP note_NN 12_CD ._.
Financial_NNP commitments_NNS i_FW Capital_NN expenditure_NN 2003_CD 2002_CD m_NN m_NN Contracted_VBD 7.8_CD 1.2_CD ii_NN Manufacturing_NNP capacity_NN The_NNP Group_NNP has_VBZ entered_VBN into_IN significant_JJ manufacturing_NN capacity_NN arrangements_NNS as_IN discussed_VBN below_IN :_: Sandoz_NNP formerly_RB Biochemie_NNP GmbH_NNP Celltech_NNP has_VBZ contracted_VBN Sandoz_NNP ,_, a_DT subsidiary_NN of_IN Novartis_NNP ,_, as_IN a_DT long-term_JJ source_NN for_IN the_DT manufacture_NN of_IN its_PRP$ microbially_RB produced_VBN antibody_NN products_NNS including_VBG CDP870_NNP ._.
Celltech_NNP has_VBZ reserved_VBN manufacturing_VBG capacity_NN beginning_VBG 1_CD January_NNP 2004_CD and_CC ending_VBG 31_CD December_NNP 2010_CD ._.
Celltech_NNP has_VBZ potential_JJ take_NN or_CC pay_NN obligations_NNS ,_, which_WDT are_VBP subject_JJ to_TO mitigation_NN ,_, under_IN this_DT agreement_NN of_IN approximately_RB 41_CD million_CD ._.
Lonza_NNP Celltech_NNP has_VBZ contracted_VBN Lonza_NNP as_IN a_DT long-term_JJ manufacturing_NN source_NN and_CC has_VBZ reserved_VBN manufacturing_VBG capacity_NN until_IN 31_CD December_NNP 2010_CD ._.
Under_IN the_DT contract_NN there_EX are_VBP varying_VBG sums_NNS payable_JJ each_DT year_NN under_IN take_NN or_CC pay_NN obligations_NNS ._.
The_DT total_JJ obligations_NNS over_IN the_DT period_NN of_IN the_DT contract_NN ,_, which_WDT are_VBP subject_JJ to_TO mitigation_NN ,_, amount_NN to_TO 14_CD million_CD ._.
BioReliance_NNP Celltech_NNP has_VBZ a_DT contract_NN with_IN BioReliance_NNP enabling_VBG the_DT Group_NNP to_TO reserve_VB manufacturing_VBG capacity_NN ._.
The_DT current_JJ minimum_NN commitment_NN is_VBZ 2.2_CD million_CD based_VBN on_IN forecast_NN requirements_NNS which_WDT have_VBP been_VBN submitted_VBN to_TO BioReliance_NNP ._.
iii_FW Leasing_NNP Operating_NN and_CC finance_NN lease_NN commitments_NNS are_VBP disclosed_VBN in_IN note_NN 19_CD ._.
Celltech_NNP Annual_JJ Report_NNP 2003_CD 73_CD Notes_NNS to_TO the_DT Financial_NNP Statements_NNP continued_VBD 27_CD ._.
Pension_NNP arrangements_NNS The_DT Group_NNP operates_VBZ a_DT number_NN of_IN pension_NN schemes_NNS ,_, the_DT majority_NN being_VBG defined_VBN benefit_NN arrangements_NNS ._.
Details_NNS of_IN the_DT Groups_NNS schemes_NNS are_VBP as_IN follows_VBZ :_: i_FW Pension_NN schemes_NNS under_IN SSAP_NNP 24 2003 2002_CD The_DT charge_NN for_IN the_DT year_NN comprises_VBZ :_: m_VB m_FW Celltech_NNP Pension_NNP and_CC Life_NNP Assurance_NNP Scheme_NNP and_CC Medeva_NNP Plans_NNP 1.6_CD 2.2_CD US_NNP qualified_VBD scheme_NN 1.1_CD US_NNP non-qualified_JJ scheme_NN 0.2_CD 0.2_CD Thiemann_NNP plan_NN 0.6_CD 0.5_CD Defined_VBN contribution_NN schemes_NNS US_NNP and_CC UK_NNP 3.3_CD 1.6_CD Total_JJ 5.7_CD 5.6_CD The_DT defined_VBN contribution_NN schemes_NNS relate_VBP primarily_RB to_TO the_DT Celltech_NNP Group_NNP Personal_NNP Pension_NNP Plan_NNP CGPPP_NNP and_CC US_NNP 401K_NNP plans_NNS ._.
The_DT CGPPP_NNP was_VBD introduced_VBN as_IN of_IN 1_CD January_NNP 2000_CD for_IN all_DT new_JJ UK_NNP employees_NNS of_IN the_DT Group_NNP ._.
The_DT Celltech_NNP Pension_NNP and_CC Life_NNP Assurance_NNP Scheme_NNP CP&LAS_NNP ,_, the_DT Medeva_NNP UK_NNP Pension_NNP Plan_NNP and_CC the_DT Medeva_NNP Senior_NNP Executive_NNP Pension_NNP Plan_NNP are_VBP all_DT closed_VBN to_TO new_JJ members_NNS ._.
Under_IN the_DT CGPPP_NNP the_DT Group_NNP contributes_VBZ 8_CD %_NN of_IN salary_NN to_TO individual_JJ plans_NNS for_IN employees_NNS ._.
The_DT contribution_NN accrued_VBN at_IN the_DT end_NN of_IN the_DT financial_JJ year_NN in_IN respect_NN of_IN the_DT Groups_NNS UK_NNP pension_NN scheme_NN was_VBD 0.1_CD million_CD ._.
This_DT was_VBD paid_VBN in_IN accordance_NN with_IN trust_NN rules_NNS in_IN January_NNP 2004_CD ._.
Details_NNS of_IN the_DT Groups_NNS defined_VBN benefit_NN schemes_NNS are_VBP set_VBN out_RP below_IN :_: UK_NNP defined_VBD benefit_NN Scheme_NNP The_DT last_JJ full_JJ actuarial_JJ valuation_NN of_IN the_DT UK_NNP schemes_NNS for_IN SSAP_NNP 24_CD purposes_NNS was_VBD undertaken_VBN as_RB at_IN 30_CD September_NNP 2002_CD ._.
However_RB ,_, an_DT actuarial_JJ review_NN has_VBZ been_VBN carried_VBN out_RP as_IN at_IN 30_CD September_NNP 2003_CD ._.
The_DT main_JJ financial_JJ assumptions_NNS for_IN the_DT 30_CD September_NNP 2003_CD review_NN were_VBD as_IN follows_VBZ :_: Rate_NN of_IN return_NN 6.8_CD %_NN Rate_NN of_IN increase_NN in_IN salaries_NNS 4.0_CD %_NN LPI_NNP pension_NN increases_NNS 2.5_CD %_NN Revaluation_NN in_IN deferment_NN 2.5_CD %_NN Asset_NNP valuation_NN method_NN Market_NN value_NN Liability_NN valuation_NN Attained_VBN age_NN The_DT assets_NNS and_CC liabilities_NNS of_IN the_DT scheme_NN were_VBD as_IN follows_VBZ :_: 30_CD Sep_NNP 2003_CD m_NN Assets_NNS 39.6_CD Liabilities_NNS 44.6_CD Deficit_NN in_IN the_DT scheme_NN 5.0_CD The_DT CP&LAS_NNP is_VBZ thus_RB funded_VBN at_IN 89_CD %_NN of_IN the_DT liabilities_NNS ._.
The_DT attained_VBN age_NN methodology_NN is_VBZ used_VBN to_TO obtain_VB the_DT actuarial_JJ valuation_NN for_IN liabilities_NNS ._.
The_DT attained_VBN age_NN methodology_NN is_VBZ the_DT most_RBS appropriate_JJ in_IN the_DT circumstances_NNS of_IN this_DT scheme_NN ,_, which_WDT has_VBZ been_VBN closed_VBN to_TO new_JJ members_NNS ._.
The_DT cash_NN cost_NN of_IN the_DT scheme_NN is_VBZ identical_JJ to_TO the_DT profit_NN and_CC loss_NN charge_NN and_CC consequently_RB there_EX is_VBZ no_DT SSAP_NNP 24_CD prepayment_NN nor_CC provision_NN ._.
On_IN the_DT basis_NN of_IN the_DT actuarial_JJ reviews_NNS ,_, the_DT current_JJ average_JJ contribution_NN rate_NN paid_VBN by_IN the_DT Group_NNP is_VBZ 14.7_CD %_NN of_IN pensionable_JJ salaries_NNS 2002_CD :_: 14.7_CD %_NN ._.
Pension_NNP arrangements_NNS continued_VBD US_NNP Qualified_NNP Scheme_NNP The_DT most_RBS recent_JJ valuation_NN of_IN the_DT plan_NN under_IN US_NNP accounting_NN standards_NNS was_VBD carried_VBN out_RP on_IN 31_CD December_NNP 2003_CD ._.
At_IN the_DT valuation_NN date_NN ,_, the_DT market_NN value_NN of_IN the_DT assets_NNS of_IN the_DT plan_NN was_VBD 8.9_CD million_CD and_CC the_DT liabilities_NNS were_VBD 11.9_CD million_CD ._.
Thus_RB the_DT assets_NNS of_IN the_DT plan_NN represented_VBD 75_CD %_NN of_IN the_DT value_NN of_IN the_DT benefits_NNS that_WDT had_VBD accrued_VBN to_TO members_NNS ._.
The_DT projected_VBN unit_NN method_NN was_VBD used_VBN to_TO derive_VB the_DT valuation_NN above_IN and_CC the_DT key_JJ actuarial_JJ assumptions_NNS are_VBP broadly_RB in_IN line_NN with_IN those_DT set_VBN out_RP in_IN ii_NN below_IN ._.
The_DT US_NNP Qualified_NNP Scheme_NNP was_VBD frozen_VBN as_RB at_IN 31_CD December_NNP 2002_CD and_CC ,_, as_IN such_JJ ,_, no_DT further_JJ benefits_NNS accrue_VBP to_TO the_DT members_NNS ._.
US_NNP Unqualified_NNP Scheme_NNP The_DT most_RBS recent_JJ valuation_NN of_IN the_DT plan_NN under_IN US_NNP accounting_NN standards_NNS was_VBD carried_VBN out_RP on_IN 31_CD December_NNP 2003_CD ._.
The_DT liabilities_NNS of_IN this_DT unfunded_JJ scheme_NN at_IN this_DT date_NN were_VBD valued_VBN at_IN 2.6_CD million_CD ._.
However_RB ,_, the_DT Group_NNP is_VBZ carrying_VBG a_DT liability_NN in_IN creditors_NNS of_IN 2.5_CD million_CD against_IN this_DT obligation_NN ,_, and_CC also_RB holds_VBZ a_DT RABBI_NNP account_NN of_IN 2.0_CD million_CD for_IN this_DT liability_NN see_VB ii_FW below_IN ._.
The_DT US_NNP Unqualified_NNP Scheme_NNP was_VBD frozen_VBN as_RB at_IN 31_CD December_NNP 2002_CD and_CC ,_, as_IN such_JJ ,_, no_DT further_JJ benefits_NNS accrue_VBP to_TO the_DT members_NNS ._.
German_JJ Thiemann_NNP Plan_NNP The_DT most_RBS recent_JJ valuation_NN of_IN the_DT plan_NN was_VBD carried_VBN out_RP as_IN at_IN 31_CD December_NNP 2003_CD under_IN IAS_NNP 19_CD ._.
At_IN the_DT valuation_NN date_NN ,_, the_DT market_NN value_NN of_IN the_DT assets_NNS of_IN the_DT plan_NN was_VBD 6.1_CD million_CD and_CC the_DT liabilities_NNS were_VBD 12.2_CD million_CD ._.
Thus_RB the_DT assets_NNS of_IN the_DT plan_NN represented_VBD 50_CD %_NN of_IN the_DT value_NN of_IN the_DT benefits_NNS that_WDT had_VBD accrued_VBN to_TO members_NNS after_IN allowing_VBG for_IN expected_JJ future_JJ increases_NNS in_IN earnings_NNS ._.
However_RB ,_, the_DT Company_NN also_RB holds_VBZ separate_JJ insurance_NN assets_NNS of_IN 6.0_CD million_CD outside_IN of_IN the_DT scheme_NN to_TO cover_VB the_DT deficit_NN ._.
Thus_RB in_IN total_JJ there_EX are_VBP assets_NNS of_IN 12.1_CD million_CD available_JJ to_TO cover_VB the_DT liability_NN of_IN 12.2_CD million_CD as_IN set_VBN out_RP in_IN the_DT FRS_NNP 17_CD disclosures_NNS ._.
The_DT key_JJ actuarial_JJ assumptions_NNS that_WDT were_VBD used_VBN are_VBP as_IN set_VBN out_RP in_IN ii_NN below_IN ._.
ii_FW FRS_FW 17_CD disclosures_NNS The_DT Group_NNP has_VBZ adopted_VBN FRS_NNP 17_CD ,_, Retirement_NNP Benefits_NNPS ,_, to_TO the_DT extent_NN of_IN the_DT mandated_VBN disclosure_NN requirements_NNS for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2003_CD ._.
FRS_NNP 17_CD is_VBZ more_RBR prescriptive_JJ than_IN SSAP_NNP 24_CD in_IN the_DT assumptions_NNS and_CC methodology_NN that_WDT must_MD be_VB used_VBN in_IN order_NN to_TO assess_VB actuarial_JJ liabilities_NNS ._.
In_IN particular_JJ ,_, FRS_NNP 17_CD prescribes_VBZ the_DT use_NN of_IN the_DT projected_VBN unit_NN method_NN of_IN valuation_NN and_CC a_DT discount_NN rate_NN obtained_VBN from_IN corporate_JJ bonds_NNS rather_RB than_IN equities_NNS ._.
Because_IN of_IN the_DT low_JJ average_JJ age_NN of_IN the_DT members_NNS of_IN the_DT CP&LAS_NNP ,_, the_DT Group_NNP considers_VBZ the_DT SSAP_NNP 24_CD valuation_NN to_TO be_VB more_RBR relevant_JJ ._.
The_DT results_NNS of_IN the_DT FRS_NNP 17_CD review_NN are_VBP presented_VBN below_IN ._.
Qualified_VBN independent_JJ actuaries_NNS updated_VBN the_DT actuarial_JJ valuations_NNS of_IN the_DT major_JJ defined_VBN benefit_NN schemes_NNS operated_VBN by_IN the_DT Group_NNP to_TO 31_CD December_NNP 2003_CD ._.
The_DT main_JJ financial_JJ assumptions_NNS used_VBN in_IN this_DT update_VB were_VBD as_IN follows_VBZ :_: 2003 2002 2001_CD UK_NNP US_NNP Germany_NNP UK_NNP US_NNP Germany_NNP UK_NNP US_NNP Germany_NNP Assumptions_NNPS %_NN %_NN %_NN %_NN %_NN %_NN %_NN %_NN %_NN Inflation_NN assumptions_NNS 2.8_CD n_VBD a_DT 2.0_CD 2.3_CD 3.0_CD 2.0_CD 2.6_CD 3.0_CD 2.0_CD Rate_NN of_IN increase_NN in_IN salaries_NNS 4.3_CD n_VBD a_DT 3.0_CD 3.8_CD 4.1-4_CD .6_CD 3.0_CD 4.1_CD 5.0_CD 3.0_CD Rate_NN of_IN increase_NN in_IN pension_NN payment_NN 2.1-2_CD .7_CD 1.5_CD 1.9-2_CD .3_CD 2.0_CD 2.0-2_CD .6_CD 2.0_CD Discount_NNP rate_NN 5.4_CD 6.0_CD 5.3_CD 5.5_CD 6.7_CD 6.0_CD 5.9_CD 7.0_CD 6.0_CD Long-term_JJ rate_NN of_IN return_NN expected_VBN at_IN 31_CD December_NNP Equities_NNPS 7.8_CD 9.2_CD n_NN a_DT 7.5_CD 9.0_CD n_IN a_DT 7.2_CD 10.0_CD n_IN a_DT Bonds_NNP 5.4_CD 6.0_CD n_IN a_DT 4.5_CD 6.7_CD n_NN a_DT 5.0_CD 7.0_CD n_NN a_DT Insurance_NN 4.8_CD n_VBP a_DT 4.5_CD 4.5_CD n_NN a_DT 3.5_CD n_NN a_DT n_NN a_DT 3.5_CD Pension_NN fund_NN deficit_NN The_DT pension_NN fund_NN deficit_NN set_VBN out_RP below_IN under_IN FRS_NNP 17_CD is_VBZ as_IN if_IN this_DT standard_NN were_VBD fully_RB applied_VBN ._.
However_RB ,_, under_IN the_DT current_JJ accounting_NN methodology_NN SSAP_NNP 24_CD there_EX are_VBP assets_NNS and_CC provisions_NNS within_IN the_DT balance_NN sheet_NN at_IN 31_CD December_NNP 2003_CD that_WDT would_MD offset_VB the_DT effect_NN on_IN net_JJ assets_NNS see_VBP below_IN of_IN this_DT deficit_NN in_IN the_DT event_NN of_IN a_DT restatement_NN under_IN FRS_NNP 17_CD ._.
If_IN FRS_NNP 17_CD had_VBD been_VBN adopted_VBN for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2003_CD ,_, the_DT Groups_NNS net_JJ assets_NNS per_IN the_DT balance_NN sheet_NN would_MD be_VB reduced_VBN by_IN 24.2_CD million_CD 2002_CD :_: 18.4_CD million_CD ._.
Further_JJ explanation_NN of_IN this_DT adjustment_NN is_VBZ included_VBN below_IN ._.
The_DT assets_NNS and_CC liabilities_NNS of_IN the_DT major_JJ defined_VBN benefit_NN schemes_NNS operated_VBN by_IN the_DT Group_NNP at_IN 31_CD December_NNP 2003_CD as_IN calculated_VBN in_IN accordance_NN with_IN FRS_NNP 17_CD are_VBP shown_VBN on_IN page_NN 76_CD ._.
Celltech_NNP Annual_JJ Report_NNP 2003_CD 75_CD Notes_NNS to_TO the_DT Financial_NNP Statements_NNP continued_VBD 27_CD ._.
Pension_NNP arrangements_NNS continued_VBD Pension_NNP fund_NN deficit_NN continued_VBD The_DT fair_JJ value_NN of_IN the_DT schemes_NNS assets_NNS ,_, which_WDT are_VBP not_RB intended_VBN to_TO be_VB realized_VBN in_IN the_DT short_JJ term_NN and_CC may_MD be_VB subject_JJ to_TO significant_JJ change_NN before_IN they_PRP are_VBP realized_VBN ,_, and_CC the_DT present_JJ value_NN of_IN the_DT schemes_NNS liabilities_NNS ,_, which_WDT are_VBP derived_VBN from_IN cash_NN flow_NN projections_NNS over_IN long_JJ periods_NNS and_CC are_VBP thus_RB inherently_RB uncertain_JJ ,_, were_VBD :_: 2003 2002 2001_CD UK_NNP US_NNP Germany_NNP Total_NNP UK_NNP US_NNP Germany_NNP Total_NNP UK_NNP US_NNP Germany_NNP Total_NNP m_FW m_FW m_FW m_FW m_FW m_FW m_FW m_FW m_FW m_FW m_FW m_FW Scheme_FW assets_NNS Equities_NNS 32.6_CD 5.5_CD 38.1_CD 29.5_CD 4.2_CD 33.7_CD 38.5_CD 5.7_CD 44.2_CD Bonds_NNS 8.8_CD 3.4_CD 12.2_CD 2.0_CD 3.4_CD 5.4_CD 1.6_CD 2.8_CD 4.4_CD RABBI_NNP trust_NN account_NN 2.0_CD 2.0_CD 2.1_CD 2.1_CD 2.5_CD 2.5_CD Insurance_NN 0.9_CD 12.1_CD 13.0_CD 3.9_CD 11.1_CD 15.0_CD 10.0_CD 10.0_CD Total_JJ fair_JJ value_NN of_IN assets_NNS 42.3_CD 10.9_CD 12.1_CD 65.3_CD 35.4_CD 9.7_CD 11.1_CD 56.2_CD 40.1_CD 11.0_CD 10.0_CD 61.1_CD Present_JJ value_NN of_IN scheme_NN liabilities_NNS 64.1_CD 14.5_CD 12.2_CD 90.8_CD 52.1_CD 13.3_CD 11.0_CD 76.4_CD 48.0_CD 15.7_CD 9.6_CD 73.3_CD Deficit_NN in_IN the_DT scheme_NN 21.8_CD 3.6_CD 0.1_CD 25.5_CD 16.7_CD 3.6_CD 0.1_CD 20.2_CD 7.9_CD 4.7_CD 0.4_CD 12.2_CD Related_VBN deferred_VBN tax_NN credit_NN 1.5_CD 1.5_CD 1.5_CD 1.5_CD Net_JJ pension_NN fund_NN scheme_NN deficit_NN surplus_NN under_IN FRS_NNP 17_CD 21.8_CD 2.1_CD 0.1_CD 24.0_CD 16.7_CD 2.1_CD 0.1_CD 18.7_CD 7.9_CD 4.7_CD 0.4_CD 12.2_CD Adjustments_NNS for_IN existing_VBG assets_NNS and_CC provisions_NNS under_IN SSAP_NNP 24_CD Assets_NNS ,_, net_NN of_IN related_JJ deferred_JJ tax_NN 2.8_CD 2.8_CD 2.1_CD 0.5_CD 2.6_CD 2.5_CD 0.4_CD 2.9_CD Provision_NNP ,_, net_NN of_IN deferred_JJ tax_NN 0.1_CD 2.5_CD 2.6_CD 2.9_CD 2.9_CD 1.0_CD 3.0_CD 4.0_CD Adjustment_NNP to_TO FRS_NNP 17_CD ,_, net_NN of_IN related_JJ deferred_JJ tax_NN 21.7_CD 2.4_CD 0.1_CD 24.2_CD 16.7_CD 1.3_CD 0.4_CD 18.4_CD 6.9_CD 4.2_CD 11.1_CD Net_JJ assets_NNS as_IN currently_RB disclosed_VBN n_IN a_DT n_NN a_DT n_NN a_DT 505.9_CD n_NN a_DT n_NN a_DT n_NN a_DT 564.4_CD n_NN a_DT n_NN a_DT n_NN a_DT 619.2_CD Net_JJ assets_NNS as_IN adjusted_VBN if_IN FRS_NNP 17_CD were_VBD fully_RB adopted_VBN n_IN a_DT n_NN a_DT n_NN a_DT 481.7_CD n_NN a_DT n_NN a_DT n_NN a_DT 546.0_CD n_NN a_DT n_NN a_DT n_NN a_DT 608.1_CD The_DT RABBI_NNP trust_NN is_VBZ held_VBN in_IN the_DT Groups_NNS own_VBP name_NN and_CC is_VBZ shown_VBN within_IN other_JJ debtors_NNS in_IN note_NN 15_CD ._.
This_DT account_NN can_MD only_RB be_VB used_VBN by_IN the_DT Group_NNP to_TO pay_VB the_DT pension_NN liabilities_NNS of_IN the_DT US_NNP Unqualified_NNP Scheme_NNP ,_, except_IN in_IN the_DT case_NN of_IN bankruptcy_NN when_WRB it_PRP would_MD become_VB part_NN of_IN the_DT general_JJ pool_NN of_IN assets_NNS and_CC pensioners_NNS would_MD rank_VB as_IN ordinary_JJ creditors_NNS ._.
Included_VBN within_IN the_DT insurance_NN assets_NNS held_VBN in_IN Germany_NNP are_VBP 6.0_CD million_CD of_IN insurance_NN arrangements_NNS in_IN the_DT Companys_NNP own_JJ name_NN which_WDT were_VBD written_VBN in_IN order_NN to_TO cover_VB the_DT pension_NN deficits_NNS that_WDT would_MD otherwise_RB exist_VB in_IN the_DT pension_NN scheme_NN ._.
There_EX is_VBZ no_DT intention_NN to_TO use_VB these_DT assets_NNS for_IN any_DT purpose_NN other_JJ than_IN to_TO cover_VB the_DT deficit_NN and_CC ,_, accordingly_RB ,_, they_PRP have_VBP been_VBN shown_VBN as_IN part_NN of_IN the_DT available_JJ assets_NNS ._.
FRS_NNP 17_CD pension_NN charge_NN in_IN respect_NN of_IN defined_VBN benefit_NN Schemes_NNS 2003_CD 2002_CD UK_NNP US_NNP Germany_NNP Total_NNP UK_NNP US_NNP Germany_NNP Total_NNP m_FW m_FW m_FW m_FW m_FW m_FW m_FW m_FW Operating_NN profit_NN Current_JJ service_NN cost_NN 1.4_CD 0.1_CD 0.2_CD 1.7_CD 2.0_CD 1.1_CD 0.2_CD 3.3_CD Past_NNP service_NN costs_VBZ 0.2_CD 0.2_CD Gain_NN on_IN curtailment_NN 2.6_CD 2.6_CD Loss_NN on_IN RABBI_NNP trust_NN 0.2_CD 0.2_CD Settlement_NNP on_IN bulk_NN transfer_NN 0.5_CD 0.5_CD Total_JJ operating_VBG charge_NN income_NN 1.4_CD 0.1_CD 0.2_CD 1.7_CD 1.7_CD 1.3_CD 0.2_CD 0.6_CD Finance_NNP expense_NN Expected_VBN return_NN on_IN pension_NN scheme_NN assets_NNS 2.5_CD 0.6_CD 0.3_CD 3.4_CD 2.8_CD 0.7_CD 0.2_CD 3.7_CD Interest_NN charge_NN 2.9_CD 0.9_CD 0.7_CD 4.5_CD 2.9_CD 1.0_CD 0.6_CD 4.5_CD Net_JJ expense_NN 0.4_CD 0.3_CD 0.4_CD 1.1_CD 0.1_CD 0.3_CD 0.4_CD 0.8_CD Loss_NN gain_NN before_IN taxation_NN 1.8_CD 0.4_CD 0.6_CD 2.8_CD 1.8_CD 1.0_CD 0.6_CD 1.4_CD 76_CD Celltech_NNP Annual_JJ Report_NNP 2003_CD 27_CD ._.
Pension_NNP arrangements_NNS continued_VBD 2003_CD 2002_CD UK_NNP US_NNP Germany_NNP Total_NNP UK_NNP US_NNP Germany_NNP Total_NNP m_FW m_FW m_FW m_FW m_FW m_FW m_FW m_FW Consolidated_NNP statement_NN of_IN recognized_VBN gains_NNS and_CC losses_NNS Actual_JJ return_NN less_RBR expected_JJ return_NN on_IN pension_NN schemes_NNS assets_NNS 3.0_CD 0.9_CD 0.1_CD 3.8_CD 6.2_CD 1.9_CD 0.3_CD 7.8_CD Experience_NN losses_NNS gains_VBZ arising_VBG on_IN the_DT schemes_NNS liabilities_NNS 0.9_CD 0.2_CD 0.6_CD 0.5_CD 0.3_CD 0.7_CD 0.4_CD 0.6_CD Changes_NNS in_IN assumptions_NNS underlying_VBG the_DT present_JJ value_NN of_IN the_DT schemes_NNS liabilities_NNS 7.0_CD 1.9_CD 0.6_CD 9.5_CD 3.8_CD 0.5_CD 4.3_CD Actuarial_JJ loss_NN recognized_VBN 4.9_CD 1.2_CD 0.1_CD 6.2_CD 9.7_CD 1.7_CD 0.1_CD 11.5_CD Additional_JJ disclosures_NNS required_VBN by_IN FRS_NNP 17 2003 2002_CD UK_NNP US_NNP Germany_NNP Total_NNP UK_NNP US_NNP Germany_NNP Total_NNP m_FW m_FW m_FW m_FW m_FW m_FW m_FW m_FW Difference_NN between_IN the_DT expected_VBN and_CC actual_JJ return_NN on_IN scheme_NN assets_NNS :_: Amount_NNP 3.0_CD 0.9_CD 0.1_CD 3.8_CD 6.2_CD 1.9_CD 0.3_CD 7.8_CD Percentage_NN of_IN scheme_NN assets_NNS 7_CD %_NN 8_CD %_NN 1_CD %_NN 6_CD %_NN 18_CD %_NN 20_CD %_NN 2_CD %_NN 14_CD %_NN Experience_NN gains_NNS and_CC losses_NNS on_IN scheme_NN liabilities_NNS :_: Amount_NNP 0.9_CD 0.2_CD 0.6_CD 0.5_CD 0.3_CD 0.7_CD 0.4_CD 0.6_CD Percentage_NN of_IN the_DT present_JJ value_NN of_IN scheme_NN liabilities_NNS 1_CD %_NN 1_CD %_NN 5_CD %_NN 1_CD %_NN 1_CD %_NN 5_CD %_NN 4_CD %_NN 1_CD %_NN Total_JJ amount_NN recognized_VBN in_IN statement_NN of_IN total_JJ recognized_VBN gains_NNS and_CC losses_NNS :_: Amount_NNP 4.9_CD 1.2_CD 0.1_CD 6.2_CD 9.7_CD 1.7_CD 0.1_CD 11.5_CD Percentage_NN of_IN the_DT present_JJ value_NN of_IN scheme_NN liabilities_NNS 8_CD %_NN 8_CD %_NN 1_CD %_NN 7_CD %_NN 19_CD %_NN 13_CD %_NN 1_CD %_NN 15_CD %_NN The_DT movement_NN in_IN deficit_NN during_IN the_DT year_NN ended_VBD 31_CD December_NNP is_VBZ as_IN follows_VBZ :_: 2003_CD 2002_CD UK_NNP US_NNP Germany_NNP Total_NNP UK_NNP US_NNP Germany_NNP Total_NNP m_FW m_FW m_FW m_FW m_FW m_FW m_FW m_FW Deficit_NN surplus_NN in_IN schemes_NNS at_IN beginning_NN of_IN the_DT year_NN 16.7_CD 3.6_CD 0.1_CD 20.2_CD 7.9_CD 4.7_CD 0.4_CD 12.2_CD Current_JJ service_NN cost_NN 1.4_CD 0.1_CD 0.2_CD 1.7_CD 2.0_CD 1.1_CD 0.2_CD 3.3_CD Contributions_NNS 1.6_CD 1.0_CD 0.4_CD 3.0_CD 2.7_CD 1.3_CD 0.4_CD 4.4_CD Past_NNP service_NN costs_VBZ 0.2_CD 0.2_CD Other_JJ finance_NN income_NN 0.4_CD 0.3_CD 0.4_CD 1.1_CD 0.1_CD 0.3_CD 0.4_CD 0.8_CD Gains_NNS on_IN curtailment_NN 2.6_CD 2.6_CD Settlement_NNP on_IN bulk_NN transfer_NN 0.5_CD 0.5_CD Actuarial_JJ loss_NN 4.9_CD 1.2_CD 0.1_CD 6.2_CD 9.7_CD 1.7_CD 0.1_CD 11.5_CD Loss_NN on_IN RABBI_NNP trust_NN 0.2_CD 0.2_CD Exchange_NNP 0.6_CD 0.1_CD 0.7_CD 0.5_CD 0.5_CD Deficit_NN surplus_NN in_IN schemes_NNS at_IN the_DT end_NN of_IN the_DT year_NN 21.8_CD 3.6_CD 0.1_CD 25.5_CD 16.7_CD 3.6_CD 0.1_CD 20.2_CD 2003_CD 2002_CD Total_JJ Total_JJ Reserves_NNS note_VBP m_FW m_FW Profit_NN and_CC loss_NN reserve_NN excluding_VBG FRS_NNP 17_CD additional_JJ pension_NN liability_NN 340.5_CD 281.6_CD FRS_NNP 17_CD additional_JJ pension_NN liability_NN 24.2_CD 18.4_CD Profit_NN and_CC loss_NN reserve_NN 364.7_CD 300.0_CD Celltech_NNP Annual_JJ Report_NNP 2003_CD 77_CD Notes_NNS to_TO the_DT Financial_NNP Statements_NNP continued_VBD 28_CD ._.
Contingent_JJ liabilities_NNS a_DT The_DT Group_NNP has_VBZ unsecured_JJ and_CC undrawn_JJ overdraft_NN facilities_NNS of_IN 10_CD million_CD 2002_CD :_: 11_CD million_CD net_JJ see_VBP note_NN 21_CD ._.
The_DT Company_NN has_VBZ provided_VBN guarantees_NNS to_TO finance_VB companies_NNS in_IN respect_NN of_IN finance_NN leases_NNS to_TO Celltech_NNP R&D_NNP Limited_NNP not_RB exceeding_VBG 2.5_CD million_CD 2002_CD :_: 2.5_CD million_CD ,_, of_IN which_WDT 1.0_CD million_CD 2002_CD :_: 1.4_CD million_CD has_VBZ been_VBN utilised_VBN ._.
The_DT Company_NN has_VBZ also_RB provided_VBN guarantees_NNS to_TO XL_NNP Winterthur_NNP International_NNP of_IN $_$ 13.5_CD million_CD in_IN respect_NN of_IN reinsurance_NN liabilities_NNS and_CC 8_CD million_CD to_TO Sandoz_NNP in_IN respect_NN of_IN manufacturing_VBG capacity_NN arrangements_NNS ._.
b_NN The_DT principal_JJ litigation_NN in_IN which_WDT the_DT Group_NNP has_VBZ been_VBN involved_VBN in_IN 2003_CD is_VBZ discussed_VBN below_IN ._.
In_IN common_JJ with_IN most_JJS trading_NN companies_NNS ,_, Celltech_NNP and_CC various_JJ of_IN its_PRP$ subsidiary_NN undertakings_NNS are_VBP the_DT subject_NN of_IN a_DT number_NN of_IN legal_JJ claims_NNS or_CC potential_JJ claims_NNS against_IN the_DT Group_NNP ,_, the_DT outcome_NN of_IN which_WDT can_MD not_RB at_IN present_JJ be_VB determined_VBN ._.
Provision_NNP has_VBZ been_VBN made_VBN in_IN these_DT accounts_NNS for_IN all_DT liabilities_NNS which_WDT might_MD be_VB reasonably_RB expected_VBN to_TO materialise_VB from_IN these_DT claims_NNS ._.
i_FW Ionamin_NNP In_IN July_NNP 1997_CD ,_, significant_JJ health_NN concerns_NNS were_VBD raised_VBN over_IN the_DT use_NN of_IN the_DT so-called_JJ fen-phen_JJ diet_NN co-prescription_NN of_IN fenfluramine_NN and_CC phentermine_NN ._.
These_DT concerns_NNS resulted_VBD in_IN the_DT voluntary_JJ withdrawal_NN from_IN the_DT market_NN of_IN fenfluramine_NN and_CC a_DT related_VBN drug_NN dexfenfluramine_NN in_IN September_NNP 1997_CD ._.
These_DT withdrawals_NNS were_VBD followed_VBN by_IN the_DT commencement_NN of_IN a_DT significant_JJ number_NN of_IN lawsuits_NNS in_IN the_DT US_NNP against_IN manufacturers_NNS and_CC prescribers_NNS of_IN fenfluramine_NN ,_, dexfenfluramine_NN and_CC phentermine_NN ._.
The_DT most_RBS common_JJ allegation_NN is_VBZ that_IN the_DT fen-phen_JJ diet_NN caused_VBD heart_NN valve_NN problems_NNS ,_, neurological_JJ dysfunction_NN and_CC ,_, much_RB less_JJR frequently_RB ,_, primary_JJ pulmonary_JJ hypertension_NN ,_, a_DT rare_JJ ,_, frequently_RB fatal_JJ disease_NN of_IN the_DT lungs_NNS ._.
Celltech_NNP has_VBZ been_VBN named_VBN in_IN close_NN to_TO 7,000_CD of_IN these_DT cases_NNS ,_, approximately_RB 1,500_CD of_IN which_WDT were_VBD pending_VBG as_RB at_IN 31_CD December_NNP 2003_CD ._.
The_DT Groups_NNS involvement_NN derives_VBZ from_IN the_DT sale_NN by_IN a_DT Celltech_NNP subsidiary_NN ,_, since_IN 2_CD July_NNP 1996_CD ,_, of_IN lonamin_NN ,_, the_DT phentermine_NN prescription_NN pharmaceutical_JJ acquired_VBN from_IN Fisons_NNP Corporation_NNP Fisons_NNP on_IN that_DT date_NN ._.
At_IN 12_CD February_NNP 2004_CD ,_, the_DT Group_NNP had_VBD been_VBN formally_RB dismissed_VBN from_IN approximately_RB 5,370_CD of_IN these_DT cases_NNS without_IN payment_NN of_IN any_DT sums_NNS by_IN way_NN of_IN damages_NNS or_CC costs_NNS to_TO third_JJ parties_NNS ,_, and_CC dismissals_NNS of_IN more_JJR than_IN 700_CD additional_JJ cases_NNS ,_, also_RB without_IN payment_NN ,_, were_VBD agreed_VBN to_TO or_CC filed_VBN but_CC were_VBD not_RB yet_RB effective_JJ ._.
Celltech_NNP denies_VBZ liability_NN on_IN a_DT number_NN of_IN grounds_NNS ,_, including_VBG ,_, fundamentally_RB ,_, that_IN Ionamin_NNP does_VBZ not_RB cause_VB the_DT health_NN conditions_NNS complained_VBD of_IN ._.
Ionamin_NNP has_VBZ been_VBN marketed_VBN since_IN 1959_CD and_CC the_DT FDA_NNP did_VBD not_RB request_NN that_WDT Ionamin_NNP or_CC any_DT other_JJ phentermine_NN be_VB withdrawn_VBN from_IN the_DT market_NN ._.
Moreover_RB ,_, Celltech_NNP believes_VBZ it_PRP will_MD be_VB indemnified_VBN for_IN any_DT unanticipated_JJ liability_NN by_IN Fisons_NNP for_IN Ionamin_NNP sold_VBD prior_RB to_TO 2_CD July_NNP 1996_CD and_CC by_IN Celltechs_NNP product_NN liability_NN insurance_NN carriers_NNS for_IN Ionamin_NNP sold_VBD after_IN 2_CD July_NNP 1996_CD ._.
Celltechs_NNP defense_NN costs_NNS are_VBP being_VBG paid_VBN by_IN Fisons_NNP and_CC its_PRP$ insurance_NN carriers_NNS as_IN required_VBN by_IN their_PRP$ contractual_JJ indemnities_NNS ._.
Fisons_NNS indemnity_NN obligations_NNS are_VBP guaranteed_VBN by_IN Rhone_NNP Poulenc_NNP Rorer_NNP Inc_NNP ,_, now_RB part_NN of_IN Aventis_NNP Pharmaceuticals_NNP ._.
Based_VBN on_IN the_DT merits_NNS of_IN its_PRP$ defences_NNS and_CC based_VBN on_IN the_DT third_JJ party_NN insurance_NN coverage_NN benefiting_VBG Celltech_NNP discussed_VBD above_RB ,_, Celltech_NNP believes_VBZ that_IN the_DT ultimate_JJ outcome_NN of_IN this_DT litigation_NN will_MD not_RB have_VB a_DT material_NN adverse_JJ effect_NN on_IN its_PRP$ financial_JJ position_NN and_CC results_NNS of_IN the_DT operations_NNS ._.
ii_FW MedImmune_NNP Litigation_NNP relating_VBG to_TO Synagis_NNP In_IN 1998_CD Celltech_NNP granted_VBN to_TO MedImmune_NNP Inc_NNP a_DT worldwide_JJ non-exclusive_JJ licence_NN to_TO use_VB certain_JJ of_IN its_PRP$ patents_NNS in_IN relation_NN to_TO its_PRP$ humanised_JJ antibody_NN preparation_NN ,_, palivizumab_NN sold_VBN by_IN MedImmune_NNP under_IN the_DT trade_NN name_NN Synagis_NNP ._.
Celltech_NNP believe_VBP that_IN MedImmunes_NNP Synagis_NNP product_NN comes_VBZ within_IN the_DT scope_NN of_IN its_PRP$ patents_NNS and_CC that_IN accordingly_RB MedImmune_NNP owes_VBZ significant_JJ royalties_NNS to_TO Celltech_NNP ._.
MedImmune_NNP disputes_NNS this_DT and_CC have_VBP refused_VBN to_TO pay_VB any_DT royalties_NNS ._.
Accordingly_RB Celltech_NNP commenced_VBD two_CD legal_JJ actions_NNS against_IN MedImmune_NNP one_CD in_IN respect_NN of_IN the_DT US_NNP patent_NN the_DT major_JJ market_NN for_IN Synagis_NNP and_CC the_DT other_JJ in_IN respect_NN of_IN the_DT German_JJ patent_NN where_WRB Synagis_NNP is_VBZ manufactured_VBN ._.
Both_DT actions_NNS are_VBP subject_JJ to_TO the_DT jurisdiction_NN of_IN the_DT UK_NNP Courts_NNPS ._.
The_DT claim_NN with_IN respect_NN to_TO the_DT US_NNP patent_NN was_VBD dismissed_VBN by_IN the_DT High_NNP Court_NNP in_IN November_NNP 2002_CD ._.
Celltechs_NNP appeal_NN to_TO the_DT Court_NNP of_IN Appeal_NNP was_VBD dismissed_VBN by_IN a_DT majority_NN decision_NN in_IN July_NNP 2003_CD with_IN an_DT Order_NN that_WDT Celltech_NNP pay_NN MedImmunes_NNP legal_JJ costs_NNS ._.
As_IN at_IN 31_CD December_NNP 2003_CD ,_, MedImmunes_NNP claim_NN for_IN legal_JJ costs_NNS had_VBD been_VBN settled_VBN and_CC paid_VBN by_IN Celltech_NNP ._.
The_DT claim_NN with_IN respect_NN to_TO the_DT German_JJ patent_NN is_VBZ scheduled_VBN for_IN hearing_NN in_IN the_DT High_NNP Court_NNP at_IN the_DT end_NN of_IN March_NNP 2004_CD ._.
On_IN 14_CD October_NNP 2003_CD ,_, Celltech_NNP obtained_VBD the_DT grant_NN of_IN a_DT further_JJ US_NNP patent_NN which_WDT also_RB falls_VBZ within_IN the_DT scope_NN of_IN the_DT licence_NN granted_VBN to_TO MedImmune_NNP ._.
In_IN January_NNP 2004_CD ,_, MedImmune_NNP filed_VBD a_DT declaratory_JJ action_NN in_IN the_DT US_NNP District_NNP Court_NNP for_IN the_DT District_NNP of_IN Columbia_NNP in_IN respect_NN of_IN this_DT patent_NN seeking_VBG a_DT declaration_NN that_IN its_PRP$ Synagis_NNP product_NN does_VBZ not_RB infringe_VB the_DT patent_NN and_CC that_IN the_DT patent_NN is_VBZ invalid_JJ ._.
This_DT matter_NN also_RB forms_VBZ the_DT subject_NN of_IN further_JJ litigation_NN in_IN the_DT UK_NNP ._.
Since_IN the_DT scope_NN of_IN MedImmunes_NNP claims_NNS are_VBP limited_VBN to_TO seeking_VBG a_DT declaration_NN that_IN it_PRP owes_VBZ no_DT royalties_NNS in_IN respect_NN of_IN Synagis_NNP ,_, Celltech_NNP has_VBZ no_DT potential_JJ liability_NN under_IN any_DT of_IN this_DT pending_VBG litigation_NN save_VB in_IN respect_NN of_IN MedImmunes_NNP legal_JJ costs_NNS should_MD Celltechs_NNP claim_NN in_IN the_DT UK_NNP Courts_NNPS fail_VBP ._.
Litigation_NN relating_VBG to_TO Boss_NNP Cabilly_NNP patent_NN interference_NN settlement_NN On_IN 23_CD December_NNP 2003_CD ,_, the_DT US_NNP District_NNP Court_NNP for_IN the_DT Central_NNP District_NNP of_IN California_NNP granted_VBD summary_NN judgement_NN in_IN favor_NN of_IN Celltech_NNP and_CC Genentech_NNP that_IN the_DT settlement_NN of_IN the_DT Boss_NNP Cabilly_NNP patent_NN interference_NN between_IN Celltech_NNP and_CC Genentech_NNP was_VBD immune_JJ from_IN claims_NNS brought_VBN in_IN a_DT lawsuit_NN by_IN MedImmune_NNP under_IN antitrust_JJ and_CC unfair_JJ competition_NN laws_NNS ._.
On_IN 19_CD February_NNP 2004_CD the_DT Court_NNP granted_VBD final_JJ judgement_NN in_IN favor_NN of_IN Celltech_NNP and_CC Genentech_NNP on_IN those_DT causes_NNS of_IN action_NN ._.
Claims_NNS by_IN MedImmune_NNP against_IN Genentech_NNP that_IN the_DT Cabilly_NNP patent_NN is_VBZ invalid_JJ and_CC not_RB infringed_VBN are_VBP pending_VBG in_IN the_DT same_JJ matter_NN ,_, but_CC those_DT claims_NNS were_VBD not_RB asserted_VBN against_IN Celltech_NNP ._.
MedImmune_NNP has_VBZ indicated_VBN its_PRP$ intention_NN to_TO 78_CD Celltech_NNP Annual_JJ Report_NNP 2003_CD appeal_NN the_DT judgement_NN ._.
Should_MD MedImmune_NNP appeal_NN and_CC ultimately_RB prevail_VB in_IN its_PRP$ claims_NNS ,_, Celltech_NNP would_MD be_VB liable_JJ to_TO pay_VB damages_NNS ,_, a_DT reasonable_JJ estimate_NN of_IN which_WDT can_MD not_RB be_VB made_VBN at_IN this_DT time_NN ._.
iii_FW 69kD_FW Celltech_NNP is_VBZ the_DT owner_NN of_IN patents_NNS for_IN 69kD_NNP ,_, the_DT Bordetella_NN pertussis_NN protein_NN also_RB known_VBN as_IN Pertactin_NNP ._.
Celltech_NNP has_VBZ granted_VBN GlaxoSmithKline_NNP an_DT exclusive_JJ worldwide_NN licence_NN to_TO use_VB the_DT patents_NNS ._.
Under_IN the_DT terms_NNS of_IN the_DT licence_NN ,_, Celltech_NNP has_VBZ the_DT first_JJ option_NN to_TO take_VB proceedings_NNS to_TO enforce_VB the_DT patents_NNS ._.
Litigation_NN has_VBZ arisen_VBN in_IN Europe_NNP involving_VBG Celltechs_NNP patents_NNS and_CC acellular_JJ pertussis_NN vaccines_NNS owned_VBN by_IN Chiron_NNP and_CC its_PRP$ subsidiaries_NNS ._.
On_IN 23_CD July_NNP 1998_CD ,_, Celltech_NNP issued_VBD infringement_NN proceedings_NNS in_IN Italy_NNP against_IN Chiron_NNP for_IN infringement_NN of_IN one_CD of_IN Celltechs_NNP patents_NNS relating_VBG to_TO the_DT 69kD_JJ antigen_NN and_CC is_VBZ seeking_VBG an_DT injunction_NN to_TO prevent_VB Chiron_NNP from_IN marketing_VBG its_PRP$ product_NN ._.
Chiron_NNP is_VBZ defending_VBG that_IN action_NN ,_, and_CC has_VBZ counterclaimed_VBN for_IN a_DT declaration_NN of_IN invalidity_NN of_IN the_DT patent_NN ._.
Court_NNP experts_NNS have_VBP been_VBN appointed_VBN ,_, but_CC the_DT date_NN when_WRB their_PRP$ report_NN will_MD be_VB provided_VBN is_VBZ not_RB known_VBN ._.
This_DT patent_NN is_VBZ also_RB subject_JJ to_TO opposition_NN proceedings_NNS in_IN the_DT European_JJ Patent_NNP Office_NNP brought_VBN by_IN Chiron_NNP on_IN 22_CD January_NNP 1997_CD ._.
The_DT European_JJ Patent_NNP Office_NNP has_VBZ determined_VBN ,_, in_IN a_DT decision_NN issued_VBN in_IN November_NNP 2000_CD ,_, that_IN the_DT patent_NN should_MD be_VB revoked_VBN ._.
This_DT decision_NN of_IN the_DT EPO_NNP is_VBZ the_DT subject_NN of_IN an_DT appeal_NN by_IN Celltech_NNP which_WDT will_MD be_VB heard_VBN on_IN 19_CD March_NNP 2004_CD ._.
iv_NN Lonza_NNP On_IN 14_CD July_NNP 2003_CD ,_, Celltech_NNP announced_VBD that_IN it_PRP had_VBD entered_VBN into_IN a_DT long-term_JJ supply_NN agreement_NN with_IN Lonza_NNP ,_, under_IN which_WDT Lonza_NNP will_MD manufacture_VB PEGylated_NNP antibody_NN fragment_NN based_VBN drugs_NNS for_IN Celltech_NNP at_IN its_PRP$ microbial_JJ production_NN facility_NN ._.
At_IN the_DT same_JJ time_NN ,_, Celltech_NNP and_CC Lonza_NNP announced_VBD a_DT settlement_NN for_IN the_DT termination_NN of_IN the_DT CDP571_NNP manufacturing_NN agreement_NN ._.
The_DT Group_NNP had_VBD provided_VBN as_RB at_IN 31_CD December_NNP 2002_CD for_IN managements_NNS best_JJS estimate_NN of_IN the_DT amounts_NNS expected_VBN to_TO materialise_VB from_IN the_DT termination_NN of_IN this_DT agreement_NN ._.
The_DT terms_NNS of_IN the_DT settlement_NN have_VBP not_RB resulted_VBN in_IN any_DT additional_JJ charge_NN to_TO the_DT profit_NN and_CC loss_NN account_NN ._.
v_FW Alpharma_NNP During_IN 2002_CD Celltech_NNP sold_VBD its_PRP$ Armstrong_NNP business_NN to_TO Andrx_NNP ._.
This_DT operation_NN had_VBD a_DT product_NN supply_NN contract_NN with_IN a_DT customer_NN ,_, Alpharma_NNP ._.
During_IN 2003_CD ,_, Alpharma_NNP voluntarily_RB withdrew_VBD the_DT product_NN from_IN sale_NN claiming_VBG that_IN an_DT element_NN of_IN the_DT production_NN process_NN did_VBD not_RB have_VB the_DT required_JJ FDA_NNP approval_NN ._.
They_PRP have_VBP filed_VBN a_DT suit_NN against_IN Andrx_NNP and_CC Celltech_NNP has_VBZ recently_RB been_VBN included_VBN as_IN a_DT co-defendant_NN in_IN respect_NN of_IN liabilities_NNS arising_VBG when_WRB Celltech_NNP owned_VBD the_DT Armstrong_NNP business_NN ._.
Based_VBN on_IN the_DT merits_NNS of_IN its_PRP$ defense_NN ,_, Celltech_NNP believes_VBZ that_IN the_DT ultimate_JJ outcome_NN of_IN this_DT litigation_NN will_MD not_RB have_VB a_DT material_NN adverse_JJ effect_NN on_IN the_DT financial_JJ position_NN and_CC results_NNS of_IN the_DT Company_NN ._.
However_RB ,_, if_IN the_DT Company_NN were_VBD ultimately_RB held_VBN liable_JJ ,_, the_DT damages_NNS that_WDT would_MD be_VB payable_JJ could_MD have_VB a_DT material_NN adverse_JJ effect_NN a_DT reasonable_JJ estimate_NN of_IN which_WDT can_MD not_RB be_VB made_VBN at_IN this_DT time_NN on_IN the_DT financial_JJ position_NN and_CC results_NNS of_IN operations_NNS of_IN the_DT Company_NN ._.
c_NN Self_NN insurance_NN Since_IN 20_CD September_NNP 2001_CD ,_, the_DT Group_NNP has_VBZ been_VBN required_VBN to_TO increase_VB its_PRP$ levels_NNS of_IN self_NN insurance_NN in_IN respect_NN of_IN methylphenidate_NN ._.
In_IN addition_NN ,_, the_DT Group_NNP has_VBZ decided_VBN to_TO retain_VB a_DT level_NN of_IN self_NN insurance_NN in_IN respect_NN of_IN all_DT product_NN liability_NN up_IN to_TO $_$ 13.5_CD million_CD ,_, as_RB well_RB as_IN self_NN insurance_NN in_IN respect_NN of_IN methylphenidate_NN of_IN up_RB to_TO $_$ 20_CD million_CD ._.
Whilst_NNP no_DT methylphenidate_NN claims_NNS have_VBP been_VBN received_VBN since_IN 20_CD September_NNP 2001_CD ,_, the_DT Group_NNP has_VBZ provided_VBN 5.4_CD million_CD based_VBN on_IN an_DT external_JJ review_NN of_IN the_DT likely_JJ liability_NN associated_VBN with_IN incidents_NNS that_WDT may_MD arise_VB from_IN past_JJ sales_NNS of_IN methylphenidate_NN prior_RB to_TO 20_CD September_NNP 2003_CD and_CC across_IN all_DT products_NNS after_IN 19_CD September_NNP 2003_CD ._.
Celltech_NNP Annual_JJ Report_NNP 2003_CD 79_CD Notes_NNS to_TO the_DT Financial_NNP Statements_NNP continued_VBD 29_CD ._.
Consolidated_NNP cash_NN flow_NN statements_NNS Reconciliation_NNP of_IN operating_VBG loss_NN to_TO net_JJ cash_NN outflow_NN from_IN operating_VBG activities_NNS 2003_CD 2002_CD m_NN m_NN Operating_NN loss_NN 63.6_CD 44.7_CD Operating_NN exceptional_JJ items_NNS 18.9_CD Operating_NN loss_NN before_IN exceptional_JJ costs_NNS 44.7_CD 44.7_CD Depreciation_NN 13.9_CD 13.3_CD Goodwill_NNP amortisation_NN 94.2_CD 93.7_CD Intangibles_NNP amortisation_NN 3.2_CD 1.0_CD Increase_VBP decrease_NN in_IN stocks_NNS 3.6_CD 0.1_CD Increase_VBP decrease_NN in_IN debtors_NNS 6.6_CD 0.9_CD Increase_VBP decrease_NN in_IN creditors_NNS 28.9_CD 9.7_CD Settlement_NNP of_IN fair_JJ value_NN provisions_NNS 22.5_CD Net_JJ cash_NN inflow_NN from_IN operating_VBG activities_NNS before_IN restructuring_VBG costs_NNS 62.8_CD 54.6_CD Outflow_NNP relating_VBG to_TO operating_VBG exceptional_JJ costs_NNS 5.1_CD 5.2_CD Outflow_NNP relating_VBG to_TO termination_NN of_IN operations_NNS 3.8_CD Net_JJ cash_NN inflow_NN from_IN operating_VBG activities_NNS 53.9_CD 49.4_CD Analysis_NN of_IN changes_NNS in_IN net_JJ funds_NNS At_IN Cash_NNP Exchange_NNP At_IN 1_CD Jan_NNP 2003_CD Acquisitions_NNPS flow_NN movements_NNS 31_CD Dec_NNP 2003_CD m_FW m_FW m_FW m_FW m_FW Cash_NN 81.1_CD 37.5_CD 5.1_CD 38.5_CD Liquid_NN resources_NNS 24.0_CD 99.5_CD 7.0_CD 116.5_CD Finance_NNP leases_NNS 1.7_CD 0.7_CD 1.0_CD Loans_NNPS 31.2_CD 28.5_CD 2.7_CD Net_JJ funds_NNS 72.2_CD 99.5_CD 15.3_CD 2.4_CD 154.0_CD 80_CD Celltech_NNP Annual_JJ Report_NNP 2003_CD
